Serum Nutritional Biomarkers and Their Associations with Sleep among US Adults in Recent National Surveys

May A Beydoun; Alyssa A Gamaldo; Jose A Canas; Hind A Beydoun; Mauli T Shah; Jessica M McNeely; Alan B Zonderman

doi:10.1371/journal.pone.0103490

. 2014 Aug 19;9(8):e103490. doi: 10.1371/journal.pone.0103490

Serum Nutritional Biomarkers and Their Associations with Sleep among US Adults in Recent National Surveys

May A Beydoun ^1,^*, Alyssa A Gamaldo ¹, Jose A Canas ², Hind A Beydoun ³, Mauli T Shah ^1,⁴, Jessica M McNeely ^1,⁴, Alan B Zonderman ¹

Editor: Yinglin Xia⁵

PMCID: PMC4138077 PMID: 25137304

Abstract

Background

The associations between nutritional biomarkers and measures of sleep quantity and quality remain unclear.

Methods

Cross-sectional data from the National Health and Nutrition Examination Surveys (NHANES) 2005–2006 were used. We selected 2,459 adults aged 20–85, with complete data on key variables. Five sleep measures were constructed as primary outcomes: (A) Sleep duration; (B) Sleep disorder; (C) Three factors obtained from factor analysis of 15 items and labeled as “Poor sleep-related daytime dysfunction” (Factor 1), “Sleepiness” (Factor 2) and “Sleep disturbance” (Factor 3). Main exposures were serum concentrations of key nutrients, namely retinol, retinyl esters, carotenoids (α-carotene, β-carotene, β-cryptoxanthin, lutein+zeaxanthin, lycopene), folate, vitamin B-12, total homocysteine (tHcy), vitamin C, 25-hydroxyvitamin D (25(OH)D) and vitamin E. Main analyses consisted of multiple linear, logistic and multinomial logit models.

Results

Among key findings, independent inverse associations were found between serum vitamin B-12 and sleep duration, 25(OH)D and sleepiness (as well as insomnia), and between folate and sleep disturbance. Serum total carotenoids concentration was linked to higher odds of short sleep duration (i.e. 5–6 h per night) compared to normal sleep duration (7–8 h per night).

Conclusions

A few of the selected serum nutritional biomarkers were associated with sleep quantity and quality. Longitudinal studies are needed to ascertain temporality and assess putative causal relationships.

Introduction

Serum nutritional biomarkers' role in health and disease has evolved from a marker of deficiency in one bodily system (e.g. vitamin D and bone), to non-classical metabolic roles, ultimately altering myriad of chronic conditions spanning the pulmonary, immune, digestive, muskuloskeletal, endocrine, cardiovascular, and central nervous systems (CNS). For CNS conditions, studies have linked cognitive and affective disorders (e.g. dementia, cognitive decline and depression) to variations in serum nutritional biomarkers, including carotenoids, retinol (or retinyl esters), folate, vitamin B-12, total homocysteine (tHcy), vitamin C, D and E (e.g. [1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14]). Despite this trend, and the known association between sleep and cognitive as well as affective disorders [15], [16], [17], limited epidemiological research has explored how sleep quantity and quality may be related to serum nutritional biomarkers [18], [19], [20], [21], [22], [23], [24], [25], [26].

Among those biomarkers, carotenoids were inversely related to metabolic syndrome and depressive symptoms and positively related to cardiovascular health [4], [27], [28]. Of around 40 carotenoids found in plant roots, leaves, shoots, seeds, fruit, and flowers, only a handful are ubiquitous in human serum, the most common being α-carotene, β-carotene, lutein+zeaxanthin (often grouped together), β-cryptoxanthin and lycopene [28]. Serum carotenoid concentrations are considered both markers of antioxidant capacity [29] and of total fruit and vegetable intake [28]. While dietary and/or supplemental β-carotene is the main source of pro-vitamin A, serum retinol and retinyl esters are direct measures of vitamin A bioavailability. Folate, vitamin B-12 and tHcy are often grouped as 1-C metabolism micronutrients as both folate and vitamin B-12 are needed to reduce the level of tHcy through methylation reactions in the CNS [30]. tHcy is now known to increase the risk of cardiovascular disease and as well as cognitive decline and dementia [31], while serum folate was consistently related to reduced risk of depression.(e.g. [1], [2]) Other micronutrients with known antioxidant effects are vitamins C (main dietary source: citrus fruits) and E (main dietary sources: plant oils) [32]. Finally, serum 25(OH)D, main sources: sunlight and dairy products) was specifically shown to have protective effects against cardiovascular disease [33], [34], cancer [35], [36] and infection [37], [38].

Recent research has evaluated relationships between inadequate sleep and adiposity or obesity-related metabolic disorders [39], [40], [41], [42]. Restricting sleep in a controlled setting suggested sleep's link to weight gain/obesity is explained by increases in ghrelin (the hormone stimulating appetite) and decreases in leptin (the hormone signaling satiety) [43]. Such hormonal changes can affect an individual's appetite and eating patterns. Given that eating patterns are key determinants of serum nutritional biomarker concentrations (e.g. serum folate vs. dietary quality [1]), the direct association between those biomarkers and sleep should be evaluated. Several studies have observed an association between dietary intakes of macro and micronutrients and various measures of sleep such as sleep duration, sleep onset, number of awakenings, wake after sleep, sleep medication use, total napping, obstructive sleep apnea, insomnia [44], [45], [46], [47], [48], [49], [50], [51], [52]. A recent review also discusses the possible mechanisms by which diet may influence sleep [53]. Unlike our present study, much of the previous research, has typically used dietary assessment methods that are prone to inaccurate recall of individual dietary behavior or measurement error which, in turn, may be differential by outcome status and thus bias the final measure of association possibly away from the null.

In our present study, we aimed at examining the cross-sectional associations between several nutritional biomarkers and measures of sleep quantity and quality, controlling for dietary intake of specific nutrients and supplement use as well as other potentially confounding socio-demographic, lifestyle and health-related factors, using a nationally representative sample of US adults. Although this study is largely exploratory given the paucity of evidence thus far, we hypothesize that in general, nutritional biomarkers that are linked to lower oxidative stress, including carotenoids, retinol+retinyl esters, B-vitamins (folate and B-12), vitamin C, D and E, are linked to better sleep outcomes whereas tHcy is linked to poorer outcomes.

Materials and Methods

Database and study subjects

The National Health and Nutrition Examination Surveys (NHANES) was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects/patients were approved by the Institutional Review Board of the National Center for Health Statistics, Centers for Disease Control. Written or verbal informed consent was obtained from all participants; verbal consent was witnessed and formally recorded [54].

NHANES consist of cross-sectional surveys providing nationally representative data on the health and nutritional status of the U.S. civilian population initiated in the early 1970s by the National Center for Health Statistics (NCHS), Centers for Disease Control (CDC), with waves of data being collected in non-continuous fashion. Since 1999, NHANES became a continuous survey. NHANES has a stratified, multistage probability cluster sampling design and includes an in-home interview for demographic and basic health information completed by trained staff and a health examination in a mobile examination center (MEC) completed by physicians, medical/health technicians, and dietary and health interviewers [54].

We selected adults aged 20–85 years from the NHANES 2005–2006 wave. Among the initial sample of 4,979 adults (2,387 men and 2,592 women) with complete basic demographic data (Sample 1), 3,464 had complete serum biomarker status. Among those in Sample 1, 2,980 participants had complete data on diet, physical activity, smoking status, supplement use, weight, height and serum cholesterol (Sample 2). Among those in Sample 2, complete data on sleep quality variables was available for 2,459 participants (Sample 3). Sample 3 differed from Sample 1 on some basic demographic variables: compared to those only in Sample 1, Sample 3 participants were younger, non-Hispanic white, married, above 200% of the federal poverty line, and have greater than high school education level. This information allowed adjustment for selection bias beyond the oversampling of certain groups which was adjusted by using sampling weights (See statistical analysis section).

Outcome assessment: Sleep quantity and quality measures

Sleep-related measures and scales were included in the 2005–06 NHANES as part of the Computer-Assisted Personal Interview system. The sleep questionnaire included items on sleep habits and disorders. Moreover, a subscale of eight questions, related to general productivity from the Functional Outcomes of Sleep Questionnaire [55], was also included (See Method S1 of File S1). In total, we considered 28 questions for sleep indices. The first index was a measure of sleep duration (in hours), which was also categorized into “Very short” (<5 h per night), “Short” (5–6 h per night), “Normal” (7–8 h per night), and “Long” (≥9 h per night) sleep duration, based on previous studies (e.g. [44]). The second combined all reported sleep disorders, resulting in a binary composite variable (0 = no sleep disorder; 1 = at least one sleep disorder). Those disorders included “sleep apnea”, “insomnia”, “restless leg syndrome”, and “other sleep disorders”. An exploratory factor analytic approach was used on scale items that were measured on a 5-point Likert scale reflecting poorer sleep quality with the higher score. (See Tables S1 and S2 of File S1) Three factors were extracted, rotated using varimax orthogonal rotation and predicted using the regression method. Those were labeled as: Factor 1: “Poor sleep-related daytime dysfunction”; Factor 2: “Sleepiness” and Factor 3: “Sleep disturbance”. A confirmatory factor analysis was also conducted including those three factors by constraining factor loadings that were <0.40 in the exploratory stage to be zero and the error terms to be uncorrelated. The fit of the model is presented also in Table S3 of File S1 [56].

Nutritional Biomarker assays

Using high performance liquid chromatography (HPLC) with photodiode array detection, serum concentrations of key biomarkers were measured. In this study, retinol and retinyl esters (defined as the sum of retinyl palmitate and retinyl stearate) were analyzed both separately and summed (vitamin A). Additionally, carotenoids such as α-carotene, β-carotene (cis+trans), β-cryptoxanthin, lutein+zeaxanthin, and lycopene were summed as total carotenoids (pro-vitamin A) and considered as exposures. Vitamin E was defined as the sum of α- and γ-tocopherol. Vitamin C was measured with HPLC with electrochemical detection [57], [58]. A similar grouping of serum antioxidant exposures was done elsewhere [4], [27].

Serum folate and vitamin B-12 were measured by Bio-Rad Laboratories “Quantaphase II Folate” radioassay kit [59], [60]. Serum tHcy was measured using “Abbott Homocysteine (HCY) assay”, a fully automated technique [61], [62]. Serum 25(OH)D was measured by radioimmunoassay (Diasorin Inc., Stillwater, Minnesota) [63]. Correlations between the key serum nutritional biormarkers are presented in Table S4 of File S1.

Covariates

Socio-demographic covariates included age, sex, race/ethnicity, education, marital status and family income, measured by the poverty-income ratio or the ratio of household income to the poverty line determined for that year multiplied by 100 (PIR<100% of the poverty line, 100%-<200%, ≥200%). Physical activity was measured using individual leisure-time activities that were elicited from participants in an open-ended manner. Those were coded for their intensity as assessed by metabolic equivalent (MET), which was then multiplied by duration of the activity and frequency (per week). This MET×hr/week value was summed for each participant with “none” considered sedentary (score = 0) [64], [65], [66] Cigarette smoking status was defined as “never”, “former” or “current smoker”. Previous studies found an inverse relationship between current smoking status and serum concentrations of folate and carotenoids among others [2], [27]. All NHANES participants were eligible for two 24-hr dietary recalls in the 2005–2006 wave. The first recall was administered during MEC exams, and the second 3–10 days later by telephone interview. To estimate nutrient intake in the diet, we utilized the average of the two 24-hr dietary recalls and a revised nutrient database that estimated nutrient composition per gram of USDA food code [67]. Total dietary intakes of alcohol, caffeine, fiber and selected antioxidants [total and individual carotenoids (µg/d), vitamin C and vitamin E (mg/d), folate (mcg/d), vitamin B-12 (mcg/d) and n-3 highly fatty acids (n-3 HUFA, sum of docosahexaenoice acid, eicospentaenoic acid, docosapentaenoic acid (C≥20), in g/d] were considered. Energy-adjusted associations between nutrients and outcome were obtained by entering total energy intake as a covariate. Using the MyPyramid Equivalents Database [68], cup equivalents of fruits and vegetables were estimated per individual, averaged over two 24-hr recalls. We excluded participants with only one 24-hr recall. Dietary supplement use over the past 30 days was categorized as follows: (0): non-users; (1): using one supplement; (2): using two supplements or more. Anti-depressant use was categorized with the Multum drug therapeutic category level 1 = 242 and level 2 = 249 [69], and coded as “having used an anti-depressant over the past 30 days” (1 = yes; 0 = no). Body mass index (BMI, kg.m⁻²) was computed using measured weight and height, while total cholesterol was measured with coupled reactions with cholesteryl ester hydrolase, cholesterol oxidase and peroxidase (Roche Hitachi Models 717 and 912). As a sensitivity analysis, total cholesterol was added as a covariate due to its high correlation with many of lipophillic micronutrients included in our analyses (e.g. vitamins A, D and E) [27].

Because co-morbid chronic conditions were associated with worse sleep [70], [71], [72], we adjusted for self-reported type 2 diabetes, cardiovascular disease (i.e., congestive heart failure, coronary heart disease, angina, heart attack or stroke) and cancer.

Statistical analysis

Using Stata 11.0 [73], we first differences of continuous and categorical measures across sleep duration categories using t-test (from bivariate ordinary least square (OLS) regression models comparing means of continuous variables taking normal sleep duration as the common referent) and design-based F-test, respectively. Second, we conducted multiple OLS regression models with socio-demographic, lifestyle and dietary factors as predictors of serum nutritional biomarkers, to test associations between various covariates with the key exposures of interest. Third, we tested the main associations between serum nutritional biomarkers (standardized z-scores) and the five sleep quality measures, adjusting for all covariates (entered simultaneously), using multiple OLS and logistic regression models. Four different types of models were ran for each of the outcomes of interest, specifycing main exposure variables in different ways (e.g. combining carotenoids vs. not), and compared using R² for OLS models and design-based F-test for logistic regression models. Finally, multinomial logit regression models with very short, short, and long sleep durations were compared to normal sleep duration in their association with serum nutritional biomarker levels. Moreover, we also applied multinomial logit models to obtain distinctive associations between various sleep disorders and serum nutritional biomarkers. Due to low disorder prevalence (<1%), only two categories were compared to the “none” category, namely 1 = insomnia only, 2 = all others, including sleep apnea, restless leg syndrome and multiple disorders.

In all analyses, to provide an unbiased estimate for the standard errors, given sampling design complexity, masked variance units were used to estimate variances utilizing the Taylor series linearization method. MEC exam weights were incorporated in the analysis to correct for unequal probability of sampling for certain population groups and obtain population estimates of means, proportions and regression coefficients [74]. This was done by using Stata survey commands and specifying weights, strata and primary sampling units (PSU) [73].

Given missing data particularly in sleep measures, we constructed a two-stage Heckman selection model [75], [76], as was done previously in another study using a similar sample [2], to account for potential selection bias in all main analyses.

All p-values presented are 2-tailed, with p<0.05 considered statistically significant and p<0.10 marginally significant, before correction for multiple testing. The latter was done using a familywise bonferroni procedure, with a family of hypotheses defined by the sleep outcome, assuming content independence [77]. A similar approach was adopted in a previous study with cognitive decline outcomes [78]. For the sleep measures, statistical significance criterion for p-values and p-values for trend were reduced to p = 0.05/5 = 0.010 (marginal significance: p = 0.10/5 = 0.020).

Results

Study sample characteristics

Table 1 presents the distribution of sample characteristics by sleep duration categories.Generally, participants with very short or short duration of sleep were less likely to be non-Hispanic Whites compared to those with normal sleep duration (56.3% and 67.8% vs. 77.3%). They were also less likely to be married (52.8% and 60.5% vs. 67.3%%) and to have >HS education (46.8% and 58.6% vs. 65.1%) or ≥200% PIR (55.2% and 72.2% vs. 75.6%). Similarly, the prevalence of current smoking was significantly higher among very short and short sleepers compared to normal duration sleepers (50.0% and 26.2% vs. 18.3%). Very short sleep duration was also associated with lower mean physical activity compared to normal sleep (5.2 vs. 7.9). The prevalence of type 2 diabetes, cardiovascular disease and cancer was also the lowest among normal sleepers. Compared to normal sleepers (10.6%), short sleepers were less likely to use anti-depressant medication (8.3%) whereas long sleepers were more likely to do so (20.9%). As expected, Factors 1 and 3 as well as higher prevalence of sleep disorders were directly linked to shorter sleep duration. Short and/or very short sleep duration compared to normal duration was associated with lower serum levels of retinyl esters, total carotenoids (mainly α-carotene, β-carotene and β-cryptoxanthin), vitamins C, E, folate and 25(OH)D. A very short sleep duration was associated with a higher tHcy level.

Table 1. Selected baseline characteristics of NHANES 2005–06 participants by sleep duration categories (n = 2,459)¹ ^, ².

	Sleep duration categories
	(n = 114)		(n = 775)		(n = 1307)		(n = 173)
	Very short <5 h		Short 5–6 h		Normal 7–8 h		Long ≥9 h
	Mean, %	(SE)	Mean, %	(SE)	Mean, %	(SE)	Mean, %	(SE)
Socio-demographic, lifestyle and health-related factors
Age (y)	45.3	(1.6)	45.1	(0.9)	46.0	(0.9)	47.5	(2.1)
Race/ethnicity, %⁴
Non-Hispanic White	56.3	(7.5)	67.8	(2.9)	77.3	(2.5)	70.8	(4.6)
Non-Hispanic black	25.3	(6.2)	14.8	(2.7)	6.3	(1.1)	11.4	(3.0)
Mexican-American	6.3	(1.8)	9.0	(1.1)	6.9	(1.0)	7.1	(1.6)
Other ethnicity	12.0	(4.0)	8.5	(1.5)	9.0	(1.4)	10.7	(2.4)
Married, %⁴	52.8	(4.9)	60.5	(2.5)	67.3	(1.8)	62.6	(4.9)
Education, %⁴
<High School	4.6	(1.6)	5.3	(1.0)	4.6	(0.9)	7.2	(1.9)
High School	48.6	(4.7)	36.0	(3.4)	30.3	(2.5)	40.9	(3.8)
>High School	46.8	(4.6)	58.6	(3.5)	65.1	(2.6)	51.9	(4.1)
Poverty Income Ratio, %⁴
<100%	16.4	(4.1)	9.9	(1.5)	7.1	(0.9)	14.0	(3.1)
100%-<200%	28.4	(6.0)	17.9	(2.0)	17.3	(1.4)	30.0	(4.4)
≥200%	55.2	(6.5)	72.2	(2.9)	75.6	(2.0)	59.0	(4.7)
Smoking status, %⁴
Never smoker	35.6	(4.9)	48.4	(2.1)	55.3	(2.5)	56.5	(5.4)
Former smoker	14.4	(5.8)	25.5	(1.6)	26.4	(1.8)	19.5	(4.0)
Current smoker	50.0	(7.1)	26.2	(2.3)	18.3	(1.5)	24.0	(4.3)
Physical activity, Mets.hr.wk⁻¹	5.2	(1.0)⁴	7.6	(0.7)	7.9	(0.5)	6.4	(1.1)
Body mass index, kg.m⁻²	30.2	(0.7)⁴	29.6	(0.3)⁴	27.9	(0.4)	28.5	(0.7)
Serum total cholesterol, mg/dL	204.8	(5.3)	199.4	(2.0)	200.2	(1.4)	200.6	(2.1)
History of selected chronic conditions
Type 2 diabetes, %³	16.3	(4.5)	8.2	(1.0)	6.5	(0.8)	7.0	(3.1)
Cardiovascular disease, %³	12.3	(3.6)	7.4	(1.3)	5.5	(0.9)	12.7	(3.8)
Cancer, %³	9.9	(2.9)	4.9	(0.8)	7.8	(0.5)	11.4	(3.4)
Anti-depressant medication use, % yes⁴	10.6	(3.7)	8.3	(1.6)	10.6	(0.7)	20.9	(2.7)
Sleep outcome variables
Factor 1: Poor sleep-related daytime dysfunction	+0.21	(0.19)	+0.09	(0.04)⁴	−0.07	(0.02)	+0.01	(0.11)
Factor 2: Sleepiness	+0.65	(0.11)⁴	+0.19	(0.05)⁴	−0.07	(0.02)	+0.09	(0.08)
Factor 3: Sleep disturbance	+0.71	(0.14)⁴	+0.17	(0.04)⁴	−0.13	(0.03)	−0.11	(0.08)
Sleep duration (h per night)	+3.67	(0.07)⁴	+5.74	(0.01)⁴	+7.45	(0.02)	+9.39	(0.07)⁴
Sleep disorders, %⁴	22.2	(6.3)	8.2	(1.2)	4.9	(0.8)	6.1	(3.5)
Insomnia only, %	13.7	(0.5)	4.8	(0.8)	3.9	(0.8)	5.5	(3.4)
Sleep apnea only, %	2.2	(1.7)	1.2	(0.5)	0.4	(0.2)	0.0	(0.0)
Restless leg syndrome only, %	0.8	(0.8)	0.4	(0.2)	0.0	(0.0)	0.0	(0.0)
All others and multiple, %	0.0	(0.0)	0.8	(0.4)	0.0	(0.0)	0.0	(0.0)
Nutritional biomarkers
Retinol, µmol/L	2.11	(0.07)	2.10	(0.03)	2.14	(0.02)	2.02	(0.08)
Serum retinyl esters, µmol/L	0.10	(0.01)	0.11	(0.00)⁴	0.12	(0.00)	0.12	(0.01)
Total retinol+retinyl esters, µmol/L	2.22	(0.08)	2.21	(0.03)	2.26	(0.02)	2.14	(0.08)
α-Carotene, µmol/L	0.06	(0.01)⁴	0.08	(0.00)⁴	0.10	(0.01)	0.09	(0.01)
β-Carotene, µmol/L	0.24	(0.02)⁴	0.35	(0.02)⁴	0.43	(0.02)	0.41	(0.06)
β-Cryptoxanthin, µmol/L	0.16	(0.01)	0.17	(0.01)⁴	0.19	(0.01)	0.18	(0.01)
Lutein+zeaxanthin, µmol/L	0.28	(0.01)	0.28	(0.01)	0.30	(0.01)	0.29	(0.02)
Lycopene, µmol/L	0.45	(0.02)	0.47	(0.01)	0.45	(0.01)	0.46	(0.02)
Total carotenoids, µmol/L	1.19	(0.05)⁴	1.35	(0.04)⁴	1.47	(0.03)	1.42	(0.10)
Vitamin E, µmol/L	28.6	(1.4)	28.2	(0.7)³	30.2	(0.4)	29.2	(1.1)
Vitamin C, µmol/L	47.7	(4.1)³	50.0	(1.4)⁴	56.7	(1.0)	57.6	(3.1)
Folate, nmol/L	25.7	(1.5)⁴	28.9	(1.1)⁴	32.6	(0.7)	34.4	(2.4)
Vitamin B-12, pmol/L	629.6	(231.5)	394.0	(11.5)	402.4	(9.2)	373.4	(16.0)
tHcy, µmol/L	9.2	(0.3)⁴	8.4	(0.1)	8.1	(0.1)	7.8	(0.2)
25(OH)D, ng/mL	18.0	(0.8)⁴	21.4	(0.5)³	22.5	(0.4)	23.0	(1.1)
Dietary Intakes
Total Energy Intake, kcal/d	2,182	(126)	2,375	(51)³	2,241	(38)	2,100	(83)³
Alcohol intake, g/d	10.0	(2.6)	11.2	(1.2)	10.3	(1.1)	8.2	(1.5)
Caffeine, mg/d	302.6	(39.6)⁴	191.2	(8.3)	177.9	(5.5)	155.7	(12.3)
Fiber, g/d	13.7	(1.0)⁴	15.9	(0.3)³	16.7	(0.4)	14.3	(0.7)⁴
α-carotene, µg/d	250.0	(39.7)⁴	369.0	(38.8)³	464.0	(30.5)	402.1	(67.2)
β-carotene, µg/d	1,378.1	(176.0)⁴	1,915.4	(103.8)⁴	2,437.1	(124.4)	1,871.7	(216.2)
β-Cryptoxanthin, µg/d	135.4	(24.6)	125.8	(10.1)	133.6	(6.5)	114.5	(91.2)
Lutein+zeaxanthin, µg/d	1,091.5	(140.6)⁴	1,336.3	(96.7)³	1,619.3	(95.0)	1,149.5	(130.4)⁴
Lycopene, µg/d	5,008.8	(1,146)	5,569.7	(316.3)	5,864.8	(298.3)	4,777.7	(444.3)
Total carotenoids, µg/d	8,992	(1,363)³	10,863	(460)⁴	12,492	(418)	9,785⁴	(753)
vitamin C, mg/d	86.7	(9.3)	84.2	(4.0)	92.3	(3.1)	76.5³	(4.8)
vitamin E, mg/d	6.6	(0.6)³	7.6	(0.2)	7.8	(0.2)	6.7	(0.2)⁴
n-3 HUFA, g/d	0.12	(0.02)	0.14	(0.02)	0.17	(0.01)	0.16	(0.03)
Folate, µg/d	362.0	(21.3)⁴	413.0	(8.0)	434.7	(8.9)	386.4⁴	(10.2)
Vitamin B-12, µg/d	4.7	(0.4)⁴	5.7	(0.3)	5.9	(0.2)	5.3	(0.2)³
Dietary supplement use, past 30 d
None	60.8	(5.1)	41.0	(2.2)	35.9	(1.9)	30.5	(3.0)
One	16.5	(4.6)	29.3	(2.0)	28.1	(1.8)	33.8	(4.1)
Two or more	22.6	(3.8)	29.7	(2.2)	36.0	(1.7)	35.7	(4.3)
Fruits and vegetable intake, cup equivalent/d	2.31	(0.20)	2.54	(0.10)³	2.72	(0.08)	2.23³	(0.15)

Open in a new tab

Abbreviations: 25(OH)D = 25-hydroxyvitamin D; n-3 HUFA = n-3 highly unsaturated fatty acids; NHANES = National Health and Nutrition Examination Survey; SE = Standard error; tHcy = Total homocysteine.

Values are mean±SE or percent±SE. Sampling design complexity is taken into account in all analyses. This analysis is done among participants with complete data for sleep quality variables and other key variables of interest (n = 2,459).

P-value was based on design-based F-test if row variable is categorical and t-test if row variable is continuous (comparing normal sleep to each of the other categories).

P<0.05.

⁴

P<0.01 for null hypothesis of no difference by sleep duration category.

Similar to our findings with serum total carotenoids, short and very short sleep duration compared to normal was associated with lower intake of dietary total carotenoids. These associations were noted for α-carotene, β-carotene and lutein+zeaxanthin. Moreover, shorter sleep duration (vs. normal) was associated with higher total energy intake, higher caffeine, but lower vitamin E, folate, vitamin B-12 and fruits+vegetables intakes.

On the other hand, lower intakes of a number of nutrients and food groups were linked to longer sleep duration vs. normal and those included fiber, lutein+zeaxanthin, total carotenoids, vitamin E, vitamin B-12, fruits and vegetables as well as total energy intake.

Socio-demographic, lifestyle and dietary predictors of nutritional biomarkers

Tables 2 and 3 shows independent associations among socio-demographic, lifestyle and dietary factors and nutritional biomarkers. Generally, most serum biomarker levels were positively associated with age, except for 25(OH)D. Men had higher retinol and tHcy levels whereas the reverse was true for vitamin C, total carotenoids, folate and 25(OH)D. Additionally, Non-Hispanic Whites had consistently higher retinol, folate and 25(OH)D levels but lower total carotenoids, compared to Non-Hispanic blacks and Mexican-Americans. Other racial/ethnic differences were found for vitamin E and tHcy. Being married was linked to lower tHcy but higher vitamin E, total carotenoids and 25(OH)D levels. Former/current smoker status was related to lower vitamin C, total carotenoid, and folate status. PA was associated with higher total carotenoids and 25(OH)D levels, whereas BMI was inversely related to multiple biomarkers (i.e. retinol, retinyl esters, vitamin C, total carotenoids and 25(OH)D). Moreover, a history of type 2 diabetes was associated with higher serum retinol concentration, whereas a history of cardiovascular disease was related to lower retinyl esters, vitamin E and total carotenoids levels, and a history of cancer was linked to higher vitamin E status. Anti-depressant medication use was associated with a higher serum retinol concentration. Supplement use was positively associated with most nutritional biomarkers except for vitamin B-12 and 25(OH)D, with an inverse relationship found for tHcy. Higher energy intake was associated with lower folate and carotenoid status, while higher alcohol intake was linked to higher retinol, vitamin E, tHcy and 25(OH)D levels. Caffeine intake was inversely related to serum folate concentration but positively associated with tHcy serum level. Moreover, fiber intake was inversely related to retinol but positively associated with total carotenoid status. β-carotene and lycopene were both reflected in serum, while a higher lycopene intake was positively linked to retinyl ester but inversely related to tHcy. Higher intakes of folate, vitamin B-12, vitamins C and E were marked by their higher respective serum levels. Moreover, vitamin E intake was positively while folate intake was inversely associated with tHcy. Dietary n-3 HUFA was linked to higher serum total carotenoid status. When adjusting for serum cholesterol in the models (data not shown), results were not altered.

Table 2. Socio-demographic, lifestyle and dietary predictors of nutritional biomarkers (retinol, retinyl esters, vitamin C, vitamin E and total carotenoids): OLS multiple regression analyses; NHANES 2005–06 (n = 2,459).

	Retinol µmol/L			Retinyl esters µmol/L			Vitamin C µmol/L			Vitamin E µmol/L			Total carotenoids µmol/L
	β	(SEE)	P-value	β	(SEE)	P-value	β	(SEE)	P-value	β	(SEE)	P-value	β	(SEE)	P-value
Socio-demographic, lifestyle factors
Age (y)	+0.006	(0.001)	<0.001	+0.000	(0.000)	0.061	+0.115	(0.041)	0.014	+0.204	(0.011)	<0.001	+0.004	(0.001)	0.001
Female vs. male	−0.226	(0.046)	<0.001	−0.005	(0.004)	0.20	+7.674	(2.100)	0.002	+0.161	(0.506)	0.76	+0.153	(0.034)	<0.001
Race/ethnicity
Non-Hispanic White	Ref			Ref			Ref			Ref			Ref
Non-Hispanic black	−0.244	(0.036)	<0.001	+0.003	(0.004)	0.50	+2.617	(1.633)	0.13	−2.113	(0.510)	0.001	+0.176	(0.054)	0.005
Mexican-American	−0.168	(0.029)	<0.001	−0.003	(0.005)	0.57	+0.476	(2.276)	0.84	+1.251	(0.819)	0.147	+0.175	(0.061)	0.012
Other ethnicity	−0.186	(0.031)	<0.001	−0.011	(0.004)	0.013	+1.759	(2.814)	0.54	−0.610	(1.019)	0.558	+0.117	(0.061)	0.073
Married vs. non-married	−0.037	(0.030)	0.24	−0.001	(0.003)	0.77	+0.671	(1.345)	0.63	+1.520	(0.587)	0.020	+0.114	(0.037)	0.007
Education
<High School	Ref			Ref			Ref			Ref			Ref
High School	+0.032	(0.047)	0.50	+0.005	(0.008)	0.60	−2.029	(2.527)	0.44	−0.649	(0.995)	0.70	−0.020	(0.074)	0.79
>High School	+0.018	(0.059)	0.77	+0.011	(0.007)	0.15	−1.351	(2.631)	0.62	−0.362	(0.910)	0.52	−0.095	(0.083)	0.28
Poverty Income Ratio
<100%	Ref			Ref			Ref			Ref			Ref
100%-<200%	+0.027	(0.055)	0.63	+0.000	(0.005)	0.99	−1.170	(1.460)	0.44	−0.431	(0.968)	0.66	+0.006	(0.072)	0.69
≥200%	+0.013	(0.052)	0.81	−0.004	(0.005)	0.42	+1.490	(1.392)	0.30	+0.714	(0.966)	0.47	−0.021	(0.051)	0.69
Smoking status
Never smoker	Ref			Ref			Ref			Ref			Ref
Former smoker	+0.022	(0.019)	0.28	+0.002	(0.006)	0.78	−0.921	(1.948)	0.64	−0.928	(0.669)	0.19	−0.055	(0.064)	0.69
Current smoker	−0.020	(0.033)	0.56	−0.007	(0.004)	0.12	−9.414	(1.491)	<0.001	−0.877	(0.612)	0.17	−0.257	(0.052)	<0.001
Physical activity, Mets.hr.wk⁻¹	+0.001	(0.001)	0.17	+0.000	(0.000)	0.90	+0.032	(0.032)	0.33	−0.015	(0.010)	0.14	+0.003	(0.001)	0.009
Body mass index, kg.m⁻²	−0.006	(0.002)	0.003	−0.001	(0.000)	0.001	−0.773	(0.064)	<0.001	+0.022	(0.024)	0.37	−0.028	(0.002)	<0.001
History of selected chronic conditions
Type 2 diabetes	+0.156	(0.042)	0.002	+0.006	(0.006)	0.38	−3.988	(1.930)	0.057	+1.494	(1.215)	0.24	−0.115	(0.064)	0.09
Cardiovascular disease	0.048	(0.111)	0.674	−0.016	(0.006)	0.024	−0.029	(2.627)	0.991	−3.311	(0.973)	0.004	−0.266	(0.056)	<0.001
Cancer	+0.124	(0.064)	0.071	+0.007	(0.008)	0.41	+2.501	(2.886)	0.400	+2.031	(0.714)	0.012	+0.040	(0.056)	0.48
Anti-depressant medication use	+0.127	(0.042)	0.009	−0.010	(0.005)	0.080	−1.074	(2.329)	0.65	+0.730	(1.079)	0.51	−0.099	(0.062)	0.13
Dietary Intakes
Total Energy Intake, kcal/d	+0.000	(0.000)	0.12	−0.000	(0.000)	0.10	−0.001	(0.064)	0.26	−0.000	(0.000)	0.10	−0.000	(0.000)	0.001
Alcohol intake, g/d	+0.003	(0.001)	0.001	+0.000	(0.000)	0.13	+0.045	(0.035)	0.22	+0.040	(0.012)	0.007	+0.001	(0.001)	0.19
Caffeine, mg/d	−0.000	(0.000)	0.30	−0.000	(0.000)	0.36	−0.004	(0.003)	0.26	−0.001	(0.001)	0.42	+0.000	(0.000)	0.46
Fiber, g/d	−0.005	(0.002)	0.032	+0.000	(0.000)	0.85	+0.269	(0.130)	0.06	−0.003	(0.049)	0.94	+0.007	(0.003)	0.022
α-carotene, µg/d	+0.000	(0.000)	0.62	+0.000	(0.000)	0.16	−0.001	(0.001)	0.52	−0.001	(0.001)	0.26	+0.000	(0.000)	0.07
β-carotene, µg/d	−0.000	(0.000)	0.37	+0.000	(0.000)	0.45	+0.000	(0.000)	0.45	+0.000	(0.000)	0.43	+0.000	(0.000)	0.013
β-Cryptoxanthin, µg/d	−0.000	(0.000)	0.80	−0.000	(0.000)	0.38	+0.000	(0.004)	0.94	−0.000	(0.002)	0.93	+0.000	(0.000)	0.12
Lutein+zeaxanthin, µg/d	+0.000	(0.000)	0.45	+0.000	(0.000)	0.77	−0.000	(0.000)	0.40	−0.000	(0.000)	0.65	+0.000	(0.000)	0.14
Lycopene, µg/d	+0.000	(0.000)	0.74	+0.000	(0.000)	0.009	−0.000	(0.011)	0.97	−0.000	(0.000)	0.36	+0.000	(0.000)	0.022
vitamin C, mg/d	+0.000	(0.000)	0.34	+0.000	(0.000)	0.60	+0.070	(0.011)	<0.001	+0.005	(0.004)	0.23	+0.000	(0.000)	0.50
vitamin E, mg/d	+0.002	(0.006)	0.68	+0.001	(0.001)	0.13	+0.014	(0.103)	0.89	+0.182	(0.053)	0.004	+0.002	(0.005)	0.67
n-3 HUFA, g/d	+0.024	(0.044)	0.59	−0.008	(0.007)	0.30	+1.684	(1.767)	0.36	+0.805	(1.159)	0.50	+0.221	(0.069)	0.006
Folate, µg/d	−0.000	(0.017)	0.98	+0.000	(0.000)	0.061	−0.004	(0.003)	0.25	+0.003	(0.002)	0.037	−0.000	(0.000)	0.95
Vitamin B-12, µg/d	+0.006	(0.004)	0.10	+0.010	(0.003)	0.032	+0.274	(0.122)	0.041	−0.016	(0.050)	0.75	−0.005	(0.004)	0.19
Dietary supplement use, past 30 d
None	Ref			Ref			Ref			Ref			Ref
One	+0.076	(0.037)	0.044	+0.010	(0.004)	0.032	+5.736	(1.347)	0.001	+2.803	(0.716)	0.001	+0.064	(0.035)	0.09
Two or more	+0.226	(0.030)	<0.001	+0.030	(0.003)	<0.001	+17.198	(1.480)	<0.001	+8.419	(0.778)	<0.001	+0.266	(0.036)	<0.001
Fruits and vegetable intake, cup equivalent/d	+0.000	(0.017)	0.98	−0.001	(0.002)	0.68	+0.661	(0.833)	0.44	−0.153	(0.252)	0.55	+0.033	(0.022)	0.16

Open in a new tab

Table 3. Socio-demographic, lifestyle and dietary predictors of nutritional biomarkers (folate, vitamin B-12, tHcy and 25(OH)D): OLS multiple regression analyses; NHANES 2005–06 (n = 2,459).

	Folate, nmol/L			Vitamin B-12, pmol/L			tHcy, µmol/L			25(OH)D, ng/mL
	β	(SEE)	P-value	β	(SEE)	P-value	β	(SEE)	P-value	β	(SEE)	P-value
Socio-demographic, lifestyle factors
Age (y)	+0.21	(0.03)	<0.001	+1.05	(0.29)	0.003	+0.069	(0.003)	<0.001	−0.059	(0.017)	0.004
Female vs. male	+4.23	(1.12)	0.002	+38.44	(27.89)	0.19	−1.471	(0.144)	<0.001	+1.164	(0.521)	0.041
Race/ethnicity
Non-Hispanic White	Ref			Ref			Ref
Non-Hispanic black	−4.94	(0.86)	<0.001	+39.22	(27.95)	0.18	+0.461	(0.280)	0.120	−8.363	(0.726)	<0.001
Mexican-American	−3.38	(1.36)	0.025	+168.13	(96.25)	0.10	−0.596	(0.160)	0.002	−5.212	(1.091)	<0.001
Other ethnicity	−3.33	(1.21)	0.014	−22.83	(29.32)	0.45	−0.043	(0.289)	0.88	−4.979	(0.842)	<0.001
Married vs. non-married	+1.42	(1.05)	0.19	−12.71	(39.60)	0.75	−0.252	(0.071)	0.003	+1.104	(0.842)	0.007
Education
<High School	Ref			Ref			Ref
High School	−0.49	(1.70)	0.78	−228.4	(153.5)	0.16	+0.367	(0.320)	0.27	−0.984	(1.054)	0.37
>High School	+0.42	(1.55)	0.79	−219.1	(142.1)	0.14	+0.164	(0.323)	0.35	−1.256	(0.905)	0.19
Poverty Income Ratio
<100%	Ref			Ref			Ref			Ref
100%-<200%	−0.84	(1.01)	0.42	+32.20	(87.55)	0.72	−0.383	(0.400)	0.35	+0.772	(0.823)	0.36
≥200%	+0.33	(0.96)	0.73	−1.03	(67.59)	0.99	−0.515	(0.407)	0.23	+0.174	(0.854)	0.84
Smoking status
Never smoker	Ref			Ref			Ref			Ref
Former smoker	−1.73	(0.93)	0.082	−57.44	(24.1)	0.031	+0.065	(0.152)	0.68	−0.221	(0.414)	0.60
Current smoker	−2.82	(0.83)	0.004	−44.67	(26.36)	0.11	+0.468	(0.246)	0.08	−0.437	(0.505)	0.40
Physical activity, Mets.hr.wk⁻¹	−0.010	(0.013)	0.52	−0.164	(0.492)	0.74	−0.007	(0.005)	0.15	+0.027	(0.010)	0.020
Body mass index, kg.m⁻²	−0.05	(0.11)	0.64	−2.969	(1.551)	0.075	−0.014	(0.010)	0.19	−0.264	(0.029)	<0.001
History of selected chronic conditions
Type 2 diabetes	+0.02	(1.12)	0.99	+193.64	(161.91)	0.25	−0.013	(0.229)	0.95	−0.864	(0.680)	0.22
Cardiovascular disease	+3.03	(2.00)	0.15	−59.19	(53.65)	0.29	+0.628	(0.302)	0.06	−1.348	(0.9810	0.19
Cancer	−0.52	(1.66)	0.76	+105.79	(140.68)	0.46	+0.189	(0.175)	0.30	+0.706	(0.648)	0.29
Anti-depressant medication use	−0.64	(0.98)	0.53	−6.37	(39.19)	0.87	−0.252	(0.313)	0.08	+0.763	(0.436)	0.10
Dietary Intakes
Total Energy Intake, kcal/d	−0.001	(0.000)	0.015	−0.005	(0.011)	0.63	−0.000	(0.000)	0.98	+0.000	(0.000)	0.82
Alcohol intake, g/d	−0.010	(0.014)	0.50	+0.509	(0.499)	0.32	+0.012	(0.005)	0.037	+0.033	(0.012)	0.015
Caffeine, mg/d	−0.010	(0.002)	0.002	−0.039	(0.035)	0.28	+0.001	(0.000)	0.020	+0.001	(0.001)	0.30
Fiber, g/d	−0.047	(0.079)	0.57	+1.206	(1.923)	0.54	−0.018	(0.010)	0.09	−0.005	(0.030)	0.87
α-carotene, µg/d	−0.000	(0.001)	0.66	+0.000	(0.003)	0.97	−0.000	(0.000)	0.40	+0.000	(0.000)	0.89
β-carotene, µg/d	−0.000	(0.000)	0.58	−0.002	(0.006)	0.79	−0.000	(0.000)	0.69	−0.000	(0.000)	0.92
β-Cryptoxanthin, µg/d	−0.002	(0.003)	0.57	+0.014	(0.038)	0.72	−0.000	(0.000)	0.59	−0.000	(0.001)	0.84
Lutein+zeaxanthin, µg/d	−0.000	(0.000)	0.35	+0.000	(0.003)	0.96	+0.000	(0.000)	0.38	+0.000	(0.000)	0.45
Lycopene, µg/d	−0.000	(0.000)	0.18	−0.000	(0.001)	0.95	−0.000	(0.000)	0.016	−0.000	(0.000)	0.45
vitamin C, mg/d	+0.009	(0.008)	0.29	+0.108	(0.140)	0.45	−0.000	(0.001)	0.66	−0.002	(0.003)	0.95
vitamin E, mg/d	−0.125	(0.107)	0.26	−0.291	(2.063)	0.89	+0.026	(0.010)	0.029	+0.003	(0.06)	0.95
n-3 HUFA, g/d	+0.690	(1.354)	0.62	+18.026	(33.896)	0.60	−0.328	(0.235)	0.18	−1.007	(0.596)	0.11
Folate, µg/d	+0.017	(0.002)	<0.001	+0.080	(0.050)	0.13	−0.002	(0.000)	0.002	+0.001	(0.001)	0.20
Vitamin B-12, µg/d	−0.025	(0.049)	0.61	+0.502	(1.400)	0.73	+0.003	(0.013)	0.79	+0.126	(0.027)	<0.001
Dietary supplement use, past 30 d
None	Ref			Ref			Ref			Ref
One	+5.01	(1.20)	0.001	+45.32	(26.78)	0.009	−0.407	(0.165)	0.027	+1.542	(0.343)	<0.001
Two or more	+11.98	(1.42)	<0.001	+90.42	(30.34)	0.25	−0.792	(0.159)	<0.001	+2.666	(0.446)	0.22
Fruits and vegetable intake, cup equivalent/d	+0.48	(0.39)	0.23	−0.54	(8.31)	0.95	+0.040	(0.067)	0.56	0.327	(0.202)	0.13

Open in a new tab

Abbreviations: 25(OH)D = 25-hydroxyvitamin D; n-3 HUFA = n-3 highly unsaturated fatty acids; NHANES = National Health and Nutrition Examination Survey; SEE = Standard error of the estimate; tHcy = Total homocysteine.

Nutritional biomarkers' association with sleep quantity and quality

Nutritional biomarkers' independent associations with sleep quantity and quality are shown in Table 4 . In Model 1, serum nutritional biomarkers were entered separately as predictors along with other covariates. After familywise Bonferroni correction (type I error reduced to 0.01), a significant inverse association was found between sleep disorders and 25(OH)D level (per SD = 8.7 ng/mL: OR = 0.72; 95% CI: 0.58–0.91, p = 0.008). A shorter sleep duration was associated with a higher serum level of vitamin B-12 (per SD = 1154.4 pmol/L: β = −0.07±0.02, P = 0.002). Examining the three factors of sleep quality, inverse associations of Factor 1 (poor sleep-related daytime dysfunction) with retinyl esters, Factor 2 (Sleepiness) with 25(OH)D, and Factor 3 (Sleep disturbance) with three serum nutritional biomarkers (lutein+zeaxanthin, vitamin C and folate) were observed.

Table 4. Associations between serum nutritional biomarkers (per 1 SD increase) and sleep quality measures: Multiple OLS and logistic regression models, controlling for dietary intakes or supplement use: 2-stage Heckman selection models (N = 2,346); NHANES 2005–06¹.

	Sleep duration		Sleep disorders			Factor 1: Poor sleep-related daytime dysfunction		Factor 2: Sleepiness		Factor 3: Sleep disturbance
	β ±SEE	p-value	OR	(95% CI)	p- value	β±SEE	p-value	β±SEE	p- value	β±SEE	p- value
MODEL 1 ²
Retinol, per 0.63 µmol/L	−0.05±0.03	0.19	0.78	(0.60;1.03)	0.08	−0.01±0.02	0.58	+0.01±0.02	0.69	+0.03±0.02	0.13
	R² = 0.0753		F(9,7) = 4.05, p = 0.039			R² = 0.0714		R² = 0.0943		R² = 0.0586
Retinyl esters, per 0.08 µmol/L	+0.03±0.02	0.24	0.80	(0.55;1.17)	0.23	−0.05±0.02	0.007	−0.02±0.02	0.37	+0.01±0.01	0.50
	R² = 0.0748		F(9,7) = 1.99, p = 0.19			R² = 0.0739		R² = 0.0945		R² = 0.0578
α-Carotene, per 0.09 µmol/L	−0.01±0.02	0.64	0.82	(0.52;1.31)	0.38	−0.03±0.01	0.019	−0.02±0.02	0.34	+0.01±0.02	0.76
	R² = 0.074		F(9,7) = 0.39, p = 0.91			R² = 0.0724		R² = 0.0948		R² = 0.0578
β-Carotene, per 0.47 µmol/L	−0.02±0.03	0.54	0.70	(0.43;1.15)	0.15	−0.04±0.02	0.07	+0.06±0.03	0.047	−0.04±0.02	0.07
	R² = 0.0745		F(9,7) = 1.18, p = 0.42			R² = 0.0727		R² = 0.0979		R² = 0.0592
β-Cryptoxanthin, per 0.18 µmol/L	+0.01±0.04	0.78	0.91	(0.51;1.61)	0.73	−0.00±0.02	0.99	+0.06±0.03	0.015	−0.09±0.03	0.017
	R² = 0.0744		F(9,7) = 1.56, p = 0.28			R² = 0.0713		R² = 0.0973		R² = 0.0624
Lutein+zeaxanthin, per 0.17 µmol/L	−0.02±0.03	0.60	0.69	(0.51;0.94)	0.022	+0.02±0.01	0.26	+0.00±0.02	0.91	−0.05±0.01	0.007
	R² = 0.0745		F(9,7) = 1.44, p = 0.32			R² = 0.0716		R² = 0.0942		R² = 0.0601
Lycopene, per 0.21 µmol/L	−0.02±0.04	0.61	0.87	(0.67;1.13)	0.27	−0.01±0.02	0.50	+0.03±0.02	0.07	+0.00±0.02	0.81
	R² = 0.0746		F(9,7) = 2.71, p = 0.10			R² = 0.0715		R² = 0.0953		R² = 0.0577
Vitamin E, per 12.2 µmol/L	−0.00±0.03	0.92	0.81	(0.61;1.09)	0.15	−0.04±0.02	0.034	−0.03±0.03	0.25	+0.01±0.02	0.78
	R² = 0.0744		F(9,7) = 4.26, p = 0.034			R² = 0.0730		R² = 0.0949		R² = 0.0578
Vitamin C, per 26.6 µmol/L	+0.04±0.05	0.42	0.80	(0.65;0.98)	0.037	−0.00±0.03	0.97	−0.04±0.03	0.18	−0.05±0.02	0.006
	R² = 0.0751		F(9,7) = 0.72, p = 0.68			R² = 0.0713		R² = 0.0956		R² = 0.0603
Folate, per 20.3 nmol/L	+0.05±0.02	0.07	0.86	(0.60;1.22)	0.36	−0.03±0.02	0.06	−0.04±0.02	0.028	−0.07±0.03	0.005
	R² = 0.0753		F(9,7) = 1.36, p = 0.35			R² = 0.0721		R² = 0.0958		R² = 0.0622
Vitamin B-12, per 1154.4 pmol/L	−0.07±0.02	0.002	0.93	(0.36;2.49	0.88	−0.01±0.01	0.53	+0.02±0.01	0.09	+0.03±0.01	0.08
	R² = 0.0758		F(9,7) = 1.62, p = 0.27			R² = 0.0713		R² = 0.0945		R² = 0.0581
tHcy, per 4.9 µmol/L	−0.09±0.03	0.011	0.87	(0.52;1.48)	0.60	−0.02±0.03	0.38	+0.02±0.03	0.42	+0.02±0.02	0.36
	R² = 0.0764		F(9,7) = 5.63, p = 0.016			R² = 0.0717		R² = 0.0945		R² = 0.0581
25(OH)D, per 8.7 ng/mL	+0.07±0.04	0.10	0.72	(0.58;0.91)	0.008	+0.01±0.02	0.72	−0.08±0.03	0.004	−0.02±0.03	0.43
	R² = 0.0766		F(9,7) = 2.02, p = 0.18			R² = 0.0714		R² = 0.1010		R² = 0.0581
MODEL 2 ³	R² = 0.0842		F(9,7) = 2.72, p = 0.10			R² = 0.0785		R² = 0.1193		R² = 0.0744
Retinol, per 0.63 µmol/L	−0.06±0.04	0.12	0.89	(0.69;1.16)	0.37	+0.00±0.02	0.94	+0.04±0.02	0.10	+0.03±0.02	0.036
Retinyl esters, per 0.08 µmol/L	+0.05±0.03	0.14	0.94	(0.66;1.35)	0.74	−0.03±0.02	0.09	−0.01±0.02	0.72	+0.02±0.03	0.41
α-Carotene, per 0.09 µmol/L	−0.01±0.03	0.81	1.04	(0.75;1.46)	0.79	−0.02±0.02	0.20	−0.09±0.02	0.002	+0.05±0.02	0.05
β-Carotene, per 0.47 µmol/L	−0.03±0.05	0.48	0.78	(0.51;1.21)	0.25	−0.03±0.02	0.17	+0.09±0.03	0.003	−0.03±0.02	0.17
β-Cryptoxanthin, per 0.18 µmol/L	+0.03±0.05	0.56	1.25	(0.71;2.19)	0.41	+0.01±0.02	0.62	+0.06±0.03	0.027	−0.08±0.04	0.07
Lutein+zeaxanthin, per 0.17 µmol/L	−0.01±0.04	0.72	0.74	(0.53;1.05)	0.09	+0.04±0.01	0.005	−0.02±0.02	0.45	−0.05±0.02	0.034
Lycopene, per 0.21 µmol/L	−0.03±0.05	0.55	0.98	(0.74;1.30)	0.90	+0.00±0.02	0.91	+0.03±0.02	0.12	+0.01±0.02	0.48
Vitamin E, per 12.2 µmol/L	−0.00±0.03	0.89	0.96	(0.70;1.30)	0.76	−0.04±0.03	0.12	−0.05±0.02	0.05	+0.03±0.03	0.38
Vitamin C, per 26.6 µmol/L	+0.03±0.05	0.62	0.87	(0.69;1.10)	0.22	+0.01±0.03	0.71	−0.03±0.03	0.25	−0.02±0.01	0.19
Folate, per 20.3 nmol/L	+0.03±0.03	0.19	0.96	(0.71;1.28)	0.74	−0.02±0.01	0.21	−0.02±0.02	0.36	−0.07±0.02	0.003
Vitamin B-12, per 1154.4 pmol/L	−0.08±0.03	0.006	1.07	(0.56;2.06)	0.82	−0.00±0.01	0.75	+0.03±0.01	0.043	+0.03±0.01	0.029
tHcy, per 4.9 µmol/L	−0.07±0.03	0.015	0.80	(0.47;1.38)	0.41	−0.03±0.03	0.28	+0.01±0.02	0.62	+0.01±0.03	0.78
25(OH)D, per 8.7 ng/mL	+0.08±0.04	0.10	0.77	(0.62;0.96)	0.022	+0.01±0.02	0.47	−0.09±0.03	0.005	−0.02±0.02	0.52
MODEL 3 ⁴
Total retinol+retinyl esters, per 0.64 µmol/L	−0.04±0.03	0.24	0.77	(0.58;1.03)	0.08	−0.02±0.02	0.38	+0.01±0.02	0.78	+0.03±0.02	0.11
	R² = 0.0751		F(9,7) = 2.86, p = 0.09			R² = 0.0716		R² = 0.0942		R² = 0.0587
Total carotenoids, per 0.82 µmol/L	−0.02±0.03	0.45	0.70	(0.48;1.03)	0.07	−0.03±0.02	0.18	+0.05±0.03	0.07	−0.04±0.02	0.032
	R² = 0.0746		F(9,7) = 0.91, p = 0.56			R² = 0.0721		R² = 0.0970		R² = 0.0596
MODEL 4 ⁵	R² = 0.0828		F(9,7) = 3.39, p = 0.06			R² = 0.0747		R² = 0.1091		R² = 0.0678
Total retinol+retinyl esters, per 0.64 µmol/L	−0.06±0.04	0.17	0.89	(0.67;1.19)	0.41	−0.00±0.02	0.97	+0.03±0.02	0.18	+0.04±0.01	0.011
Total carotenoids, per 0.82 µmol/L	−0.04±0.04	0.32	0.78	(0.51;1.20)	0.25	−0.02±0.02	0.39	+0.07±0.03	0.029	−0.04±0.02	0.044
Vitamin E, per 12.2 µmol/L	+0.01±0.04	0.81	0.92	(0.69;1.23)	0.56	−0.03±0.02	0.15	−0.04±0.02	0.10	+0.02±0.02	0.39
Vitamin C, per 26.6 µmol/L	+0.03±0.05	0.56	0.87	(0.69;1.11)	0.24	+0.01±0.03	0.64	−0.03±0.03	0.31	−0.03±0.01	0.043
Folate, per 20.3 nmol/L	+0.04±0.03	0.12	0.96	(0.71;1.29)	0.75	−0.03±0.01	0.05	−0.02±0.02	0.27	−0.06±0.02	0.005
Vitamin B-12, per 1154.4 pmol/L	−0.08±0.03	0.006	1.08	(0.57;2.07)	0.80	−0.00±0.01	0.71	+0.02±0.01	0.024	+0.03±0.01	0.042
tHcy, per 4.9 µmol/L	−0.08±0.03	0.015	0.80	(0.47;1.37)	0.40	−0.03±0.03	0.28	+0.01±0.02	0.58	+0.01±0.03	0.80
25(OH)D, per 8.7 ng/mL	+0.07±0.04	0.11	0.77	(0.61;0.96)	0.024	+0.01±0.02	0.55	−0.08±0.02	0.005	−0.01±0.02	0.57

Open in a new tab

Abbreviations: BMI = Body Mass Index; CI = confidence interval; Met = Metabolic Equivalent; n-3 HUFA = omega-3 highly unsaturated fatty acids; NHANES = National Health and Nutrition Examination Survey; OR = odds ratio; SEE = Standard error of the estimate.

Values are odds ratios with 95% confidence intervals or β±SEE. Sampling design complexity is taken into account in all analyses.

Model 1 included each nutritional biomarker exposure separately and adjusted for socio-demographic factors: age, sex, race/ethnicity, marital status, educational level and poverty income ratio, and other potential confounders: Lifestyle and health-related factors (smoking status, BMI, physical activity: Mets.hr.wk⁻¹, history of selected chronic conditions (i.e. type 2 diabetes, CVD and cancer)), anti-depressant use and dietary intakes (total energy intake, alcohol, caffeine, fiber, n-3 HUFA, each of the five carotenoids, vitamin C, vitamin E, folate, vitamin B-12), fruit and vegetable intake, supplement use, anti-depressant use, and the inverse mills ratio, 2-stage Heckman selection model.

Model 2 included all serum nutritional biomarker exposures simultaneously, controlling for the same covariate as above.

⁴

Model 3 is model 1 (i.e. controlling for the same covariates as above) but with main exposures being total retinol+retinyl esters and total carotenoids. The other nutritional biomarkers are not shown because their results were already presented in model 1.

⁵

Model 4 is model 2 (i.e. controlling for the same covariates as above) but with main exposures being total retinol+retinyl esters, total carotenoids and the other serum nutritional biomarkers entered into the model simultaneously.

In model 2, when all serum nutritional biomarkers were entered into the same model simultaneously along with potential confounding covariates, some of the previously observed inverse associations remained significant (though slightly attenuated), but not others. In particular, after correction for multiple testing, while the association between 25(OH)D and sleep disorders became non-significant, the inverse relationship between 25(OH)D and poor sleep quality was retained with respect to Factor 2 (Sleepiness) (p = 0.005). A consistent association was noted for vitamin B-12 with sleep duration and for folate with Factor 3 (Sleep disturbance). However, other associations emerged due to covarying all those nutritional biomarkers together in the same model, particularly individual carotenoids. Most notably, lutein+zeaxanthin were associated with Factor 1, reflecting a deleterious effect on poor sleep-related daytime dysfunction (for each 1 SD = 0.17; β = +0.04±0.01, p = 0.005). Moreover, while α-carotene showed an independent inverse association with Factor 2 (Sleepiness), a positive association was found between β-carotene and this factor.

In model 3, all nutritional biomarkers were entered separately (as in model 1) while combining total carotenoids and retinol+retinyl esters together as two main exposures and adjusting for the same covariates. None of the associations for combined total carotenoids and retinol+retinyl esters with the five sleep measures were significant after correcting for multiple testing.

In model 4, all nutritional biomarkers were entered simultaneously (as in model 2), while combining total carotenoids and retinol+retinyl esters together as two main exposures and adjusting for the same covariates. In this model, significant inverse relationships (p<0.010) were consistently found between vitamin B-12 and sleep duration, 25(OH)D and Factor 2 (Sleepiness), folate and Factor 3 (Sleep disturbance). These associations were not altered when serum total cholesterol was included among potentially confounding factors in model 4.

Sleep disorders and their association with serum nutritional biomarkers

Using the same approach as for model 4 ( Table 4 ) and a multiple multinomial logit regression models with outcome being sleep disorder categorized as (0 = none, 1 = insomnia only, 2 = all others), we found that with each 1 SD higher serum level of 25(OH)D there was a 33% lower odds of insomnia (Relative Risk Ratio, RRR = 0.67, 95% CI:0.56–0.80, p<0.001) ( Figures 1A–1B ). All other findings were either null or did not survive familywise bonferroni correction.

*Abbreviations*: BMI = Body Mass Index; CI = confidence interval; Met = Metabolic Equivalent; n-3 HUFA = omega-3 highly unsaturated fatty acids; NHANES = National Health and Nutrition Examination Survey; RRR = relative risk ratio; SEE = Standard error of the estimate. ^a Values are Relative Risk Ratios (RRR) with 95% confidence intervals. Sampling design complexity is taken into account in all analyses. ^b Models included all serum nutritional biomarker exposures simultaneously, and adjusted for socio-demographic factors: age, sex, race/ethnicity, marital status, educational level and poverty income ratio, and other potential confounders: Lifestyle and health-related factors (smoking status, BMI, physical activity: Mets.hr.wk⁻¹, history of selected chronic conditions (i.e. type 2 diabetes, CVD and cancer)), anti-depressant use and dietary intakes (total energy intake, alcohol, caffeine, fiber, n-3 HUFA, each of the five carotenoids, vitamin C, vitamin E, folate, vitamin B-12), fruit and vegetable intake, supplement use, anti-depressant use, and the inverse mills ratio, 2-stage Heckman selection model as well as serum cholesterol (See **Table 4** **, Model 4** for more details).

Sleep durations and their association with serum nutritional biomarkers

Another multinomial logit model ( Figures 2A–2C ) was conducted with very short, short and long sleep durations being compared to normal sleep duration in their association with serum nutritional biomarker levels, using a similar approach as in Model 4 ( Table 4 ). When the sub-group with very short sleep duration (<5 h per night) was contrasted with normal sleep duration (i.e. 7–8 h per night), only a marginal negative association was found with 25(OH)D and very short sleep (per SD: RRR = 0.74, 95%CI:0.53–1.03, p = 0.07), which did not survive multiple testing correction, ( Figure 2A ). In Figure 2B , short sleep (5–6 h per night) was contrasted to normal sleep duration (7–8 h per night). In this case, total carotenoid concentration was linked to increased risk of short sleep (RRR = 1.15, 95%CI:1.04–1.26, p = 0.007), which remained significant after multiple testing correction. Finally, when examining long sleep duration ≥(9 h per night) vs. normal, we found a negative association between vitamin B-12 and extended sleep durations (RRR = 0.29, 95% CI:0.10–0.80, p = 0.021), an association that did not survive multiple testing correction ( Figure 2C ).

Discussion

To our knowledge, this is the first nationally representative study to examine the association between serum nutritional biomarkers and sleep (quantity and quality) among US adults. Among key findings, independent inverse associations were found between serum vitamin B-12 and sleep duration, 25(OH)D and sleepiness (as well as insomnia), and between folate and sleep disturbance. Serum total carotenoid concentration was linked to higher odds of short sleep duration (i.e. 5–6 h per night) compared to normal sleep duration (7–8 h per night).

Nutritional biomarkers, diet and sleep: previous studies

Diet and nutritional biomarkers' relationship with sleep quantity/quality and sleep disorders was examined in few previous studies, most of which useddietary intakes as the main exposure.(e.g. [44], [45], [46], [47], [48], [49], [50], [51]) For instance, a recent study of 87 adults (21–45 y), found that insomniacs consumed significantly less energy, carbohydrates, folic acid and vitamin B-12 than normal sleepers [48]. Another study reported that vitamin B-12 intake had a positive psychotropic alerting effect and a distribution of the sleep-wake cycle toward sleep reduction [19]. This specific finding was similar in our study, given that we found serum vitamin B-12 to be associated with shorter sleep duration and a lower propensity for longer sleep duration.

A recent NHANES 2007–08 study observed that sleep duration was associated with dietary intake of various macro and micronutrients. Specifically, short sleep duration was correlated with greater/reduced theobromine, greater/reduced Vitamin C, greater/reduced tap water consumption, greater/reduced lutein+zeaxanthin, greater/reduced lycopene, greater/reduced carbohydrate, greater/reduced selenium. In contrast, long sleep durations were correlated with greater/reduced dodecanoic acid, greater/reduced choline, and greater/reduced alcohol consumption [44].

Another similar NHANES 2007–08 study found that doubling dietary nutrient amount was related to odds of some sleep-related symptoms, but not others, as follows: (1) Difficulty falling asleep: α-carotene (OR = 0.96), selenium (OR = 0.80), dodecanoic acid (OR = 0.91), calcium (OR = 0.83) and hexadecanoic acid (OR = 1.10); (2) Difficulty maintaining sleep: salt (OR = 1.19), butanoic acid (0.81), carbohydrate (OR = 0.71), dodecanoic acid (OR = 0.90), vitamin D (OR = 0.84), lycopene (OR = 0.98), hexanoic acid (OR = 1.25) and moisture (OR = 1.27); (3) Non-restorative sleep: butanoic acid (OR = 1.09), calcium (OR = 0.81), vitamin C (OR = 0.92), water (OR = 0.98), moisture (OR = 1.41) and cholesterol (OR = 1.10); (4) Sleepiness: moisture (OR = 1.20), theobromine (OR = 1.04), potassium (OR = 0.70) and water (OR = 0.97) [52]. Although those two studies examined a large number of dietary nutrient intakes rather than a smaller number of serum nutritional biomarkers, the latter found a putative protective effect of vitamin D on certain aspects of sleep quality [52]. In addition, our study found that lutein+zeaxanthin was associated with poorer daytime dysfunction independently of other carotenoid and biomarker levels. This finding is similar to the observed shortened sleep duration associated with intake of lutein+zeaxanthin in one of the two recent studies using NHANES 2007–08 [44]. In contrast to the previous study [52], however, the current study did not observe a significant association between sleep latency and α-carotene intake, but did observe an inverse relationship between α-carotene and sleepiness.

Many studies with serum nutritional biomarkers as predictors of sleep have commonalities with the present study's results, with a few showing an opposite trend. In terms of the relationship between serum 25(OH)D and sleep, low levels in one study was correlated with excessive daytime sleepiness among blacks but not among whites in a consecutive sample of 81 sleep clinic patients [18]. This finding was highly comparable to ours. Given that we had a larger sample size, we found this result in the entire multi-ethnic NHANES sample. In addition, we found an association between 25(OH)D and lower risk of sleep disorders which did not survive correction for multiple testing (0.01≤p<0.05), though was significant in the case of insomnia. In contrast, this association was found specifically for obstructive sleep apnea and restless leg syndrome in two previous studies [21], [22]. In contrast to our findings, Day and colleagues [20] found that patients with obstructive lung apnea, as compared to controls, had lower serum levels of retinyl palmitate and 9-cis retinoic acid, as well as lower levels of all-trans-β-carotene and 9-cis-β-carotene. Moreover, low serum folate has been associated with restless leg syndrome among pregnant women [23]. Higher tHcy was linked to an increased risk of obstructive sleep apnea in some studies [24], [25] but not others [79], [80]. Despite evidence of a protective effect of vitamins C and E on sleep quality [26], [44], [81], our study did not find an independent association between these two antioxidants and the sleep measures under study.

Potential biological mechanisms of the association of B-vitamins, vitamin D and pro-vitamin A carotenoids with sleep

The sleep-wake cycle is controlled by a master clock in the suprachiasmatic nuclei of the hypothalamus and is reset daily by retina-perceived light [82]. Folate and vitamin B-12 allow remethylation of homocysteine to methionine, thereby improving histone and DNA methylation patterns [83]. These patterns are associated with daily endogenous circadian rhythmicity of the clock protein PER2 [84] and the neuropeptide vasopressin, in the suprachiasmatic nuclei [85]. As a result, these effects entrain the endogenous circadian component of sleep propensity [86] and increase light sensitivity and photic synchronization by affecting melatonin metabolism [87]. However, as stated earlier, a positive psychotropic alerting effect of vitamin B-12 was found in a previous study, possibly due to a distribution of the sleep-wake cycle toward sleep reduction [19]. Moreover, this study suggested that increasing levels of vitamin B-12 may lead to faster decline in melatonin levels, thus reducing the odds of longer sleep duration.

Vitamin D receptors are abundantly expressed in the anterior and posterior hypothalamus, substantia nigra, midbrain central gray, raphe nuclei, and the nucleus reticularis pontis oralis and caudalis, which appear to coordinate the sleep-wake state and the paralysis of the bulbar and somatic musculature during sleep [88]. There may be a narrow range of 25(OH)vitamin D3 blood levels that are necessary to produce normal sleep and clinical trials are needed to determine the effects of Vitamin D3 replacement in the prevention of sleep disorders such as insomnia, obstructive sleep apnea and rapid eye movement related apnea [89].

The importance of Pro-Vitamin A carotenoids and its derivatives on gene transcription in the CNS are presumed to be mediated largely by retinoic acid and its isomer 9-cis-RA interactions with its nuclear receptors RAR and RXR [90]. Recently, it was reported that RARβ (an RAR subtype) gene expression in the hypothalamus determines delta oscillation's contribution in mouse sleep electroencephalogram (EEG) patterns [91]. A 4-week dietary deficiency of vitamin A (VAD) causes the attenuation of delta power in sleep and spontaneous activity in mice. Similarly, chronic administration of LE540, an antagonist of RARs, attenuated wakefulness and EEG delta power during non-rapid eye movement sleep leading to hypo-expression of dopamine D1 receptors and a shortened sleep-wake cycle [92]. In our study, serum total carotenoid concentration was linked to higher odds of short sleep duration (i.e. 5–6 h per night) compared to normal sleep duration (7–8 h per night).

Strengths and limitations

Our study has numerous strengths. These include using a large nationally representative sample which collected data on a wide range of nutritional biomarkers, and the use of a comprehensive screening instrument to obtain several measures of sleep quality, rather than focusing solely on sleep duration and/or sleep disorders, as was done in previous studies. Limitations of our study, include using a crude measure for dietary supplements and self-reported sleep measures, the study's cross-sectional design which precluded causal inference through ascertaining directionality of relationships, the self-reported sleep measures, the relatively high proportion of missing data from original eligible adult sample resulting in potential selection bias, and residual confounding by unmeasured covariates.

Conclusion

In sum, a few of the selected serum nutritional biomarkers were associated with sleep quantity and quality. In particular, there was a consistent association indicative of a potential protective effect of serum 25(OH)D and folate on two dimensions of sleep quality, namely sleepiness and sleep disturbance. In contrast, total carotenoids were positively associated with shorter sleep duration and a similar deleterious effect of serum vitamin B-12 on sleep duration was found. This highlights the specificity of each of those micronutrients in their relationship with sleep. However, longitudinal studies are needed in which baseline nutritional biomarkers are modeled against change in sleep measures to ascertain temporality and assess putative causal relationships.

Supporting Information

File S1

Sleep quality-related measures; factor analysis approach and results; Correlation matrix between biomarkers. Method S1, Sleep quality-related measures and factor analytic approach. Table S1, Rotated three-factor model solution: All 21 items. Table S2, Rotated three-factor model solution: reduced to 15 items. Table S3, Confirmatory factor analysis with 15 items, related fit indices, and correlation between EFA and CFA predicted factors. Table S4, Correlation matrix between key serum nutritional biomarkers.

(DOC)

Click here for additional data file.^{(133KB, doc)}

Acknowledgments

We would like to thank Dr. Melissa Kitner-Triolo and Dr. Wayne Chan (NIA/NIH/IRP) for internally reviewing our manuscript.

Funding Statement

This study was entirely supported by the National Institute on Aging, Intramural Research Program (NIA/NIH/IRP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Beydoun MA, Fanelli Kuczmarski MT, Beydoun HA, Shroff MR, Mason MA, et al. (2010) The sex-specific role of plasma folate in mediating the association of dietary quality with depressive symptoms. J Nutr 140: 338–347. [DOI] [PMC free article] [PubMed] [Google Scholar]
2. Beydoun MA, Shroff MR, Beydoun HA, Zonderman AB (2010) Serum folate, vitamin B-12, and homocysteine and their association with depressive symptoms among U.S. adults. Psychosom Med 72: 862–873. [DOI] [PMC free article] [PubMed] [Google Scholar]
3. Oishi J, Doi H, Kawakami N (2009) Nutrition and depressive symptoms in community-dwelling elderly persons in Japan. Acta Med Okayama 63: 9–17. [DOI] [PubMed] [Google Scholar]
4. Beydoun MA, Beydoun HA, Boueiz A, Shroff MR, Zonderman AB (2013) Antioxidant status and its association with elevated depressive symptoms among US adults: National Health and Nutrition Examination Surveys 2005–6. Br J Nutr 109: 1714–1729. [DOI] [PMC free article] [PubMed] [Google Scholar]
5. Cherubini A, Martin A, Andres-Lacueva C, Di Iorio A, Lamponi M, et al. (2005) Vitamin E levels, cognitive impairment and dementia in older persons: the InCHIANTI study. Neurobiol Aging 26: 987–994. [DOI] [PubMed] [Google Scholar]
6. Schmidt R, Hayn M, Reinhart B, Roob G, Schmidt H, et al. (1998) Plasma antioxidants and cognitive performance in middle-aged and older adults: results of the Austrian Stroke Prevention Study. J Am Geriatr Soc 46: 1407–1410. [DOI] [PubMed] [Google Scholar]
7. Dunn JE, Weintraub S, Stoddard AM, Banks S (2007) Serum alpha-tocopherol, concurrent and past vitamin E intake, and mild cognitive impairment. Neurology 68: 670–676. [DOI] [PubMed] [Google Scholar]
8. Ravaglia G, Forti P, Lucicesare A, Pisacane N, Rietti E, et al. (2008) Plasma tocopherols and risk of cognitive impairment in an elderly Italian cohort. Am J Clin Nutr 87: 1306–1313. [DOI] [PubMed] [Google Scholar]
9. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, et al. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346: 476–483. [DOI] [PubMed] [Google Scholar]
10. Clarke R, Birks J, Nexo E, Ueland PM, Schneede J, et al. (2007) Low vitamin B-12 status and risk of cognitive decline in older adults. Am J Clin Nutr 86: 1384–1391. [DOI] [PubMed] [Google Scholar]
11. Milaneschi Y, Hoogendijk W, Lips P, Heijboer AC, Schoevers R, et al. (2013) The association between low vitamin D and depressive disorders. Mol Psychiatry [DOI] [PubMed] [Google Scholar]
12. Soni M, Kos K, Lang IA, Jones K, Melzer D, et al. (2012) Vitamin D and cognitive function. Scand J Clin Lab Invest Suppl 243: 79–82. [DOI] [PubMed] [Google Scholar]
13. Annweiler C, Allali G, Allain P, Bridenbaugh S, Schott AM, et al. (2009) Vitamin D and cognitive performance in adults: a systematic review. Eur J Neurol 16: 1083–1089. [DOI] [PubMed] [Google Scholar]
14. Kang JH, Cook NR, Manson JE, Buring JE, Albert CM, et al. (2009) Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women's Antioxidant and Cardiovascular Study. Circulation 119: 2772–2780. [DOI] [PMC free article] [PubMed] [Google Scholar]
15. Blackwell T, Yaffe K, Ancoli-Israel S, Redline S, Ensrud KE, et al. (2011) Association of sleep characteristics and cognition in older community-dwelling men: the MrOS sleep study. Sleep 34: 1347–1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
16. Ohayon MM, Vecchierini MF (2005) Normative sleep data, cognitive function and daily living activities in older adults in the community. Sleep 28: 981–989. [PubMed] [Google Scholar]
17. Schmutte T, Harris S, Levin R, Zweig R, Katz M, et al. (2007) The relation between cognitive functioning and self-reported sleep complaints in nondemented older adults: results from the Bronx aging study. Behav Sleep Med 5: 39–56. [DOI] [PubMed] [Google Scholar]
18. McCarty DE, Reddy A, Keigley Q, Kim PY, Marino AA (2012) Vitamin D, race, and excessive daytime sleepiness. J Clin Sleep Med 8: 693–697. [DOI] [PMC free article] [PubMed] [Google Scholar]
19. Mayer G, Kroger M, Meier-Ewert K (1996) Effects of vitamin B12 on performance and circadian rhythm in normal subjects. Neuropsychopharmacology 15: 456–464. [DOI] [PubMed] [Google Scholar]
20. Day RM, Matus IA, Suzuki YJ, Yeum KJ, Qin J, et al. (2009) Plasma levels of retinoids, carotenoids and tocopherols in patients with mild obstructive sleep apnoea. Respirology 14: 1134–1142. [DOI] [PMC free article] [PubMed] [Google Scholar]
21. Balaban H, Yildiz OK, Cil G, Senturk IA, Erselcan T, et al. (2012) Serum 25-hydroxyvitamin D levels in restless legs syndrome patients. Sleep Med 13: 953–957. [DOI] [PubMed] [Google Scholar]
22. Bozkurt NC, Cakal E, Sahin M, Ozkaya EC, Firat H, et al. (2012) The relation of serum 25-hydroxyvitamin-D levels with severity of obstructive sleep apnea and glucose metabolism abnormalities. Endocrine 41: 518–525. [DOI] [PubMed] [Google Scholar]
23. Lee KA, Zaffke ME, Baratte-Beebe K (2001) Restless legs syndrome and sleep disturbance during pregnancy: The role of folate and iron. JOURNAL OF WOMEN'S HEALTH & GENDER-BASED MEDICINE 10: 335–341. [DOI] [PubMed] [Google Scholar]
24. Lavie L, Perelman A, Lavie P (2001) Plasma homocysteine levels in obstructive sleep apnea: association with cardiovascular morbidity. Chest 120: 900–908. [DOI] [PubMed] [Google Scholar]
25. Chen M, Wu B, Ye X, Zhou Z, Yue X, et al. (2011) Association between plasma homocysteine levels and obstructive sleep apnoea in patients with ischaemic stroke. J Clin Neurosci 18: 1454–1457. [DOI] [PubMed] [Google Scholar]
26. Grebe M, Eisele HJ, Weissmann N, Schaefer C, Tillmanns H, et al. (2006) Antioxidant vitamin C improves endothelial function in obstructive sleep apnea. Am J Respir Crit Care Med 173: 897–901. [DOI] [PubMed] [Google Scholar]
27. Beydoun MA, Shroff MR, Chen X, Beydoun HA, Wang Y, et al. (2011) Serum antioxidant status is associated with metabolic syndrome among U.S. adults in recent national surveys. J Nutr 141: 903–913. [DOI] [PMC free article] [PubMed] [Google Scholar]
28. Voutilainen S, Nurmi T, Mursu J, Rissanen TH (2006) Carotenoids and cardiovascular health. Am J Clin Nutr 83: 1265–1271. [DOI] [PubMed] [Google Scholar]
29. Krinsky NI (1993) Actions of carotenoids in biological systems. Annu Rev Nutr 13: 561–587. [DOI] [PubMed] [Google Scholar]
30. Bottiglieri T (2005) Homocysteine and folate metabolism in depression. Prog Neuropsychopharmacol Biol Psychiatry 29: 1103–1112. [DOI] [PubMed] [Google Scholar]
31. Homocysteine. A factor in cardiovascular and memory health? Mayo Clin Health Lett 20: 6. [PubMed] [Google Scholar]
32. Soory M (2009) Relevance of nutritional antioxidants in metabolic syndrome, ageing and cancer: potential for therapeutic targeting. Infect Disord Drug Targets 9: 400–414. [DOI] [PubMed] [Google Scholar]
33. Poole KE, Loveridge N, Barker PJ, Halsall DJ, Rose C, et al. (2006) Reduced vitamin D in acute stroke. Stroke 37: 243–245. [DOI] [PubMed] [Google Scholar]
34. Giovannucci E, Liu Y, Hollis BW, Rimm EB (2008) 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 168: 1174–1180. [DOI] [PMC free article] [PubMed] [Google Scholar]
35. Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, et al. (2007) Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 103: 708–711. [DOI] [PubMed] [Google Scholar]
36. Lin J, Manson JE, Lee IM, Cook NR, Buring JE, et al. (2007) Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med 167: 1050–1059. [DOI] [PubMed] [Google Scholar]
37. Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, et al. (2006) Epidemic influenza and vitamin D. Epidemiol Infect 134: 1129–1140. [DOI] [PMC free article] [PubMed] [Google Scholar]
38. Laaksi I, Ruohola JP, Tuohimaa P, Auvinen A, Haataja R, et al. (2007) An association of serum vitamin D concentrations <40 nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr 86: 714–717. [DOI] [PubMed] [Google Scholar]
39. Cappuccio FP, Taggart FM, Kandala NB, Currie A, Peile E, et al. (2008) Meta-analysis of short sleep duration and obesity in children and adults. Sleep 31: 619–626. [DOI] [PMC free article] [PubMed] [Google Scholar]
40. Watanabe M, Kikuchi H, Tanaka K, Takahashi M (2010) Association of short sleep duration with weight gain and obesity at 1-year follow-up: a large-scale prospective study. Sleep 33: 161–167. [DOI] [PMC free article] [PubMed] [Google Scholar]
41. Patel SR, Hu FB (2008) Short sleep duration and weight gain: a systematic review. Obesity (Silver Spring) 16: 643–653. [DOI] [PMC free article] [PubMed] [Google Scholar]
42. Van Cauter E, Spiegel K, Tasali E, Leproult R (2008) Metabolic consequences of sleep and sleep loss. Sleep Med 9 Suppl 1: S23–28. [DOI] [PMC free article] [PubMed] [Google Scholar]
43. Spiegel K, Leproult R, L'Hermite-Baleriaux M, Copinschi G, Penev PD, et al. (2004) Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. J Clin Endocrinol Metab 89: 5762–5771. [DOI] [PubMed] [Google Scholar]
44. Grandner MA, Jackson N, Gerstner JR, Knutson KL (2013) Dietary nutrients associated with short and long sleep duration. Data from a nationally representative sample. Appetite 64: 71–80. [DOI] [PMC free article] [PubMed] [Google Scholar]
45. Lichstein KL, Payne KL, Soeffing JP, Heith Durrence H, Taylor DJ, et al. (2007) Vitamins and sleep: an exploratory study. Sleep Med 9: 27–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
46. Grandner MA, Kripke DF, Naidoo N, Langer RD (2010) Relationships among dietary nutrients and subjective sleep, objective sleep, and napping in women. Sleep Med 11: 180–184. [DOI] [PMC free article] [PubMed] [Google Scholar]
47. Kim S, DeRoo LA, Sandler DP (2011) Eating patterns and nutritional characteristics associated with sleep duration. Public Health Nutr 14: 889–895. [DOI] [PMC free article] [PubMed] [Google Scholar]
48. Zadeh SS, Begum K (2011) Comparison of nutrient intake by sleep status in selected adults in Mysore, India. Nutr Res Pract 5: 230–235. [DOI] [PMC free article] [PubMed] [Google Scholar]
49. Imaki M, Hatanaka Y, Ogawa Y, Yoshida Y, Tanada S (2002) An epidemiological study on relationship between the hours of sleep and life style factors in Japanese factory workers. J Physiol Anthropol Appl Human Sci 21: 115–120. [DOI] [PubMed] [Google Scholar]
50. Huang W, Shah S, Long Q, Crankshaw AK, Tangpricha V (2013) Improvement of pain, sleep, and quality of life in chronic pain patients with vitamin D supplementation. Clin J Pain 29: 341–347. [DOI] [PubMed] [Google Scholar]
51. Haghighatdoost F, Karimi G, Esmaillzadeh A, Azadbakht L (2012) Sleep deprivation is associated with lower diet quality indices and higher rate of general and central obesity among young female students in Iran. Nutrition 28: 1146–1150. [DOI] [PubMed] [Google Scholar]
52. Grandner MA, Jackson N, Gerstner JR, Knutson KL (2013) Sleep symptoms associated with intake of specific dietary nutrients. J Sleep Res [DOI] [PMC free article] [PubMed] [Google Scholar]
53. Peuhkuri K, Sihvola N, Korpela R (2012) Diet promotes sleep duration and quality. Nutr Res 32: 309–319. [DOI] [PubMed] [Google Scholar]
54.(CDC) CfDCaP National Health and Nutrition Examination Survey
55. Weaver TE, Laizner AM, Evans LK, Maislin G, Chugh DK, et al. (1997) An instrument to measure functional status outcomes for disorders of excessive sleepiness. Sleep 20: 835–843. [PubMed] [Google Scholar]
56.Acock AC (2013) Discovering Structural Equation Modeling using Stata. College Station, Texas: StataCorp LP. [Google Scholar]
57.(CDC) CfDCaP (2009) National Health and Nutrition Examination Surveys (NHANES 2005–06): Laboratory Procedure Manual: Fat Soluble Micronutrients (Vitamins A, E and Carotenoids) –UV-visible Detection.
58.(CDC) CfDCaP (2009) National Health and Nutrition Examination Surveys (NHANES 2005–06): Laboratory Procedure Manual: Vitamin C.
59.(CDC) CfDCaP (2008) Centers for Disease Control and Prevention (CDC). National Health and Nutrition Examination Surveys (NHANES 2005–06): Description of Laboratory Methodology: Vitamin B-12.
60.(CDC) CfDCaP (2008) National Health and Nutrition Examination Surveys (NHANES 2005–06): Description of Laboratory Methodology: Folate.
61.Abbott Homocysteine (HCY) assay package insert fo IMX Analyzer.
62. Pernet P, Lasnier E, Vaubourdolle M (2000) Evaluation of the AxSYM homocysteine assay and comparison with the IMx homocysteine assay. Clin Chem 46: 1440–1441. [PubMed] [Google Scholar]
63.(CDC) CfDCaP (2008) National Health and Nutrition Examination Surveys (NHANES 2005–06): Description of Laboratory Methodology: Vitamin D.
64. Cheng YJ, Gregg EW, De Rekeneire N, Williams DE, Imperatore G, et al. (2007) Muscle-strengthening activity and its association with insulin sensitivity. Diabetes Care 30: 2264–2270. [DOI] [PubMed] [Google Scholar]
65. Lagerros YT, Lagiou P (2007) Assessment of physical activity and energy expenditure in epidemiological research of chronic diseases. Eur J Epidemiol 22: 353–362. [DOI] [PubMed] [Google Scholar]
66. McCullough ML, Feskanich D, Rimm EB, Giovannucci EL, Ascherio A, et al. (2000) Adherence to the Dietary Guidelines for Americans and risk of major chronic disease in men. Am J Clin Nutr 72: 1223–1231. [DOI] [PubMed] [Google Scholar]
67.United States Department of Agriculture (USDA) ARS Agriculture Research Service FSRG. Food and Nutrient Database for Dietary Studies, 3.0.
68.United States Department of Agriculture (USDA) ARS MyPyramid Equivalents Database for USDA Survey Food Codes Version 1.0
69.Center for Disease Control and Prevention (CDC) (2010) National Health and Nutrition Examination Survey 1988–2008 Data Documentation, Codebook, and Frequencies
70. Foley D, Ancoli-Israel S, Britz P, Walsh J (2004) Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey. J Psychosom Res 56: 497–502. [DOI] [PubMed] [Google Scholar]
71. Gottlieb DJ, Punjabi NM, Newman AB, Resnick HE, Redline S, et al. (2005) Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med 165: 863–867. [DOI] [PubMed] [Google Scholar]
72. Gottlieb DJ, Redline S, Nieto FJ, Baldwin CM, Newman AB, et al. (2006) Association of usual sleep duration with hypertension: the Sleep Heart Health Study. Sleep 29: 1009–1014. [DOI] [PubMed] [Google Scholar]
73.STATA (2009) Statistics/Data Analysis: Release 11.0. College Station, TX: Stata Corporation. [Google Scholar]
74.Lohr SL (2010) Sampling: Design and Analysis, 2nd Edition
75. Heckman JJ (1979) Sample selection bias as a specification error. Econometrica 47: 153–161. [Google Scholar]
76. Puhani P (2000) The Heckman Correction for sample selection and its critique. Journal of Economic Surveys 14: 53–68. [Google Scholar]
77.Hochberg Y, Tamhane, AC., (1987) Multiple comparison procedures. New York: Wiley. [Google Scholar]
78. Beydoun MA, Ding EL, Beydoun HA, Tanaka T, Ferrucci L, et al. (2012) Vitamin D receptor and megalin gene polymorphisms and their associations with longitudinal cognitive change in US adults. Am J Clin Nutr 95: 163–178. [DOI] [PMC free article] [PubMed] [Google Scholar]
79. Thakre TP, Mamtani M, Ujaoney S, Kulkarni H (2012) Association of plasma homocysteine with self-reported sleep apnea is confounded by age: results from the national health and nutrition examination survey 2005–2006. Sleep Disord 2012: 634920. [DOI] [PMC free article] [PubMed] [Google Scholar]
80. Ryan S, Nolan GM, Hannigan E, Cunningham S, Taylor C, et al. (2007) Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity. Thorax 62: 509–514. [DOI] [PMC free article] [PubMed] [Google Scholar]
81. Singh TD, Patial K, Vijayan VK, Ravi K (2009) Oxidative stress and obstructive sleep apnoea syndrome. Indian J Chest Dis Allied Sci 51: 217–224. [PubMed] [Google Scholar]
82. Golombek DA, Rosenstein RE (2010) Physiology of circadian entrainment. Physiol Rev 90: 1063–1102. [DOI] [PubMed] [Google Scholar]
83. Selhub J (1999) Homocysteine metabolism. Annu Rev Nutr 19: 217–246. [DOI] [PubMed] [Google Scholar]
84. Etchegaray JP, Lee C, Wade PA, Reppert SM (2003) Rhythmic histone acetylation underlies transcription in the mammalian circadian clock. Nature 421: 177–182. [DOI] [PubMed] [Google Scholar]
85. Ripperger JA, Merrow M (2011) Perfect timing: epigenetic regulation of the circadian clock. FEBS Lett 585: 1406–1411. [DOI] [PubMed] [Google Scholar]
86. Ohta T, Ando K, Iwata T, Ozaki N, Kayukawa Y, et al. (1991) Treatment of persistent sleep-wake schedule disorders in adolescents with methylcobalamin (vitamin B12). Sleep 14: 414–418. [PubMed] [Google Scholar]
87. Challet E, Dumont S, Mehdi MK, Allemann C, Bousser T, et al. (2013) Aging-like circadian disturbances in folate-deficient mice. Neurobiol Aging 34: 1589–1598. [DOI] [PubMed] [Google Scholar]
88. Musiol IM, Stumpf WE, Bidmon HJ, Heiss C, Mayerhofer A, et al. (1992) Vitamin D nuclear binding to neurons of the septal, substriatal and amygdaloid area in the Siberian hamster (Phodopus sungorus) brain. Neuroscience 48: 841–848. [DOI] [PubMed] [Google Scholar]
89. Gominak SC, Stumpf WE (2012) The world epidemic of sleep disorders is linked to vitamin D deficiency. Med Hypotheses 79: 132–135. [DOI] [PubMed] [Google Scholar]
90. Mey J, McCaffery P (2004) Retinoic acid signaling in the nervous system of adult vertebrates. Neuroscientist 10: 409–421. [DOI] [PubMed] [Google Scholar]
91. Maret S, Franken P, Dauvilliers Y, Ghyselinck NB, Chambon P, et al. (2005) Retinoic acid signaling affects cortical synchrony during sleep. Science 310: 111–113. [DOI] [PubMed] [Google Scholar]
92. Kitaoka K, Shimizu M, Shimizu N, Chikahisa S, Nakagomi M, et al. (2011) Retinoic acid receptor antagonist LE540 attenuates wakefulness via the dopamine D1 receptor in mice. Brain Res 1423: 10–16. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

File S1

(DOC)

Click here for additional data file.^{(133KB, doc)}

[pone.0103490-Beydoun1] 1. Beydoun MA, Fanelli Kuczmarski MT, Beydoun HA, Shroff MR, Mason MA, et al. (2010) The sex-specific role of plasma folate in mediating the association of dietary quality with depressive symptoms. J Nutr 140: 338–347. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Beydoun2] 2. Beydoun MA, Shroff MR, Beydoun HA, Zonderman AB (2010) Serum folate, vitamin B-12, and homocysteine and their association with depressive symptoms among U.S. adults. Psychosom Med 72: 862–873. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Oishi1] 3. Oishi J, Doi H, Kawakami N (2009) Nutrition and depressive symptoms in community-dwelling elderly persons in Japan. Acta Med Okayama 63: 9–17. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Beydoun3] 4. Beydoun MA, Beydoun HA, Boueiz A, Shroff MR, Zonderman AB (2013) Antioxidant status and its association with elevated depressive symptoms among US adults: National Health and Nutrition Examination Surveys 2005–6. Br J Nutr 109: 1714–1729. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Cherubini1] 5. Cherubini A, Martin A, Andres-Lacueva C, Di Iorio A, Lamponi M, et al. (2005) Vitamin E levels, cognitive impairment and dementia in older persons: the InCHIANTI study. Neurobiol Aging 26: 987–994. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Schmidt1] 6. Schmidt R, Hayn M, Reinhart B, Roob G, Schmidt H, et al. (1998) Plasma antioxidants and cognitive performance in middle-aged and older adults: results of the Austrian Stroke Prevention Study. J Am Geriatr Soc 46: 1407–1410. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Dunn1] 7. Dunn JE, Weintraub S, Stoddard AM, Banks S (2007) Serum alpha-tocopherol, concurrent and past vitamin E intake, and mild cognitive impairment. Neurology 68: 670–676. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Ravaglia1] 8. Ravaglia G, Forti P, Lucicesare A, Pisacane N, Rietti E, et al. (2008) Plasma tocopherols and risk of cognitive impairment in an elderly Italian cohort. Am J Clin Nutr 87: 1306–1313. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Seshadri1] 9. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, et al. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346: 476–483. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Clarke1] 10. Clarke R, Birks J, Nexo E, Ueland PM, Schneede J, et al. (2007) Low vitamin B-12 status and risk of cognitive decline in older adults. Am J Clin Nutr 86: 1384–1391. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Milaneschi1] 11. Milaneschi Y, Hoogendijk W, Lips P, Heijboer AC, Schoevers R, et al. (2013) The association between low vitamin D and depressive disorders. Mol Psychiatry [DOI] [PubMed] [Google Scholar]

[pone.0103490-Soni1] 12. Soni M, Kos K, Lang IA, Jones K, Melzer D, et al. (2012) Vitamin D and cognitive function. Scand J Clin Lab Invest Suppl 243: 79–82. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Annweiler1] 13. Annweiler C, Allali G, Allain P, Bridenbaugh S, Schott AM, et al. (2009) Vitamin D and cognitive performance in adults: a systematic review. Eur J Neurol 16: 1083–1089. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Kang1] 14. Kang JH, Cook NR, Manson JE, Buring JE, Albert CM, et al. (2009) Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women's Antioxidant and Cardiovascular Study. Circulation 119: 2772–2780. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Blackwell1] 15. Blackwell T, Yaffe K, Ancoli-Israel S, Redline S, Ensrud KE, et al. (2011) Association of sleep characteristics and cognition in older community-dwelling men: the MrOS sleep study. Sleep 34: 1347–1356. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Ohayon1] 16. Ohayon MM, Vecchierini MF (2005) Normative sleep data, cognitive function and daily living activities in older adults in the community. Sleep 28: 981–989. [PubMed] [Google Scholar]

[pone.0103490-Schmutte1] 17. Schmutte T, Harris S, Levin R, Zweig R, Katz M, et al. (2007) The relation between cognitive functioning and self-reported sleep complaints in nondemented older adults: results from the Bronx aging study. Behav Sleep Med 5: 39–56. [DOI] [PubMed] [Google Scholar]

[pone.0103490-McCarty1] 18. McCarty DE, Reddy A, Keigley Q, Kim PY, Marino AA (2012) Vitamin D, race, and excessive daytime sleepiness. J Clin Sleep Med 8: 693–697. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Mayer1] 19. Mayer G, Kroger M, Meier-Ewert K (1996) Effects of vitamin B12 on performance and circadian rhythm in normal subjects. Neuropsychopharmacology 15: 456–464. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Day1] 20. Day RM, Matus IA, Suzuki YJ, Yeum KJ, Qin J, et al. (2009) Plasma levels of retinoids, carotenoids and tocopherols in patients with mild obstructive sleep apnoea. Respirology 14: 1134–1142. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Balaban1] 21. Balaban H, Yildiz OK, Cil G, Senturk IA, Erselcan T, et al. (2012) Serum 25-hydroxyvitamin D levels in restless legs syndrome patients. Sleep Med 13: 953–957. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Bozkurt1] 22. Bozkurt NC, Cakal E, Sahin M, Ozkaya EC, Firat H, et al. (2012) The relation of serum 25-hydroxyvitamin-D levels with severity of obstructive sleep apnea and glucose metabolism abnormalities. Endocrine 41: 518–525. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Lee1] 23. Lee KA, Zaffke ME, Baratte-Beebe K (2001) Restless legs syndrome and sleep disturbance during pregnancy: The role of folate and iron. JOURNAL OF WOMEN'S HEALTH & GENDER-BASED MEDICINE 10: 335–341. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Lavie1] 24. Lavie L, Perelman A, Lavie P (2001) Plasma homocysteine levels in obstructive sleep apnea: association with cardiovascular morbidity. Chest 120: 900–908. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Chen1] 25. Chen M, Wu B, Ye X, Zhou Z, Yue X, et al. (2011) Association between plasma homocysteine levels and obstructive sleep apnoea in patients with ischaemic stroke. J Clin Neurosci 18: 1454–1457. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Grebe1] 26. Grebe M, Eisele HJ, Weissmann N, Schaefer C, Tillmanns H, et al. (2006) Antioxidant vitamin C improves endothelial function in obstructive sleep apnea. Am J Respir Crit Care Med 173: 897–901. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Beydoun4] 27. Beydoun MA, Shroff MR, Chen X, Beydoun HA, Wang Y, et al. (2011) Serum antioxidant status is associated with metabolic syndrome among U.S. adults in recent national surveys. J Nutr 141: 903–913. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Voutilainen1] 28. Voutilainen S, Nurmi T, Mursu J, Rissanen TH (2006) Carotenoids and cardiovascular health. Am J Clin Nutr 83: 1265–1271. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Krinsky1] 29. Krinsky NI (1993) Actions of carotenoids in biological systems. Annu Rev Nutr 13: 561–587. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Bottiglieri1] 30. Bottiglieri T (2005) Homocysteine and folate metabolism in depression. Prog Neuropsychopharmacol Biol Psychiatry 29: 1103–1112. [DOI] [PubMed] [Google Scholar]

[pone.0103490-XX1] 31. Homocysteine. A factor in cardiovascular and memory health? Mayo Clin Health Lett 20: 6. [PubMed] [Google Scholar]

[pone.0103490-Soory1] 32. Soory M (2009) Relevance of nutritional antioxidants in metabolic syndrome, ageing and cancer: potential for therapeutic targeting. Infect Disord Drug Targets 9: 400–414. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Poole1] 33. Poole KE, Loveridge N, Barker PJ, Halsall DJ, Rose C, et al. (2006) Reduced vitamin D in acute stroke. Stroke 37: 243–245. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Giovannucci1] 34. Giovannucci E, Liu Y, Hollis BW, Rimm EB (2008) 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 168: 1174–1180. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Garland1] 35. Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, et al. (2007) Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 103: 708–711. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Lin1] 36. Lin J, Manson JE, Lee IM, Cook NR, Buring JE, et al. (2007) Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med 167: 1050–1059. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Cannell1] 37. Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, et al. (2006) Epidemic influenza and vitamin D. Epidemiol Infect 134: 1129–1140. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Laaksi1] 38. Laaksi I, Ruohola JP, Tuohimaa P, Auvinen A, Haataja R, et al. (2007) An association of serum vitamin D concentrations <40 nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr 86: 714–717. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Cappuccio1] 39. Cappuccio FP, Taggart FM, Kandala NB, Currie A, Peile E, et al. (2008) Meta-analysis of short sleep duration and obesity in children and adults. Sleep 31: 619–626. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Watanabe1] 40. Watanabe M, Kikuchi H, Tanaka K, Takahashi M (2010) Association of short sleep duration with weight gain and obesity at 1-year follow-up: a large-scale prospective study. Sleep 33: 161–167. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Patel1] 41. Patel SR, Hu FB (2008) Short sleep duration and weight gain: a systematic review. Obesity (Silver Spring) 16: 643–653. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-VanCauter1] 42. Van Cauter E, Spiegel K, Tasali E, Leproult R (2008) Metabolic consequences of sleep and sleep loss. Sleep Med 9 Suppl 1: S23–28. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Spiegel1] 43. Spiegel K, Leproult R, L'Hermite-Baleriaux M, Copinschi G, Penev PD, et al. (2004) Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. J Clin Endocrinol Metab 89: 5762–5771. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Grandner1] 44. Grandner MA, Jackson N, Gerstner JR, Knutson KL (2013) Dietary nutrients associated with short and long sleep duration. Data from a nationally representative sample. Appetite 64: 71–80. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Lichstein1] 45. Lichstein KL, Payne KL, Soeffing JP, Heith Durrence H, Taylor DJ, et al. (2007) Vitamins and sleep: an exploratory study. Sleep Med 9: 27–32. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Grandner2] 46. Grandner MA, Kripke DF, Naidoo N, Langer RD (2010) Relationships among dietary nutrients and subjective sleep, objective sleep, and napping in women. Sleep Med 11: 180–184. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Kim1] 47. Kim S, DeRoo LA, Sandler DP (2011) Eating patterns and nutritional characteristics associated with sleep duration. Public Health Nutr 14: 889–895. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Zadeh1] 48. Zadeh SS, Begum K (2011) Comparison of nutrient intake by sleep status in selected adults in Mysore, India. Nutr Res Pract 5: 230–235. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Imaki1] 49. Imaki M, Hatanaka Y, Ogawa Y, Yoshida Y, Tanada S (2002) An epidemiological study on relationship between the hours of sleep and life style factors in Japanese factory workers. J Physiol Anthropol Appl Human Sci 21: 115–120. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Huang1] 50. Huang W, Shah S, Long Q, Crankshaw AK, Tangpricha V (2013) Improvement of pain, sleep, and quality of life in chronic pain patients with vitamin D supplementation. Clin J Pain 29: 341–347. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Haghighatdoost1] 51. Haghighatdoost F, Karimi G, Esmaillzadeh A, Azadbakht L (2012) Sleep deprivation is associated with lower diet quality indices and higher rate of general and central obesity among young female students in Iran. Nutrition 28: 1146–1150. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Grandner3] 52. Grandner MA, Jackson N, Gerstner JR, Knutson KL (2013) Sleep symptoms associated with intake of specific dietary nutrients. J Sleep Res [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Peuhkuri1] 53. Peuhkuri K, Sihvola N, Korpela R (2012) Diet promotes sleep duration and quality. Nutr Res 32: 309–319. [DOI] [PubMed] [Google Scholar]

[pone.0103490-CDC1] 54.(CDC) CfDCaP National Health and Nutrition Examination Survey

[pone.0103490-Weaver1] 55. Weaver TE, Laizner AM, Evans LK, Maislin G, Chugh DK, et al. (1997) An instrument to measure functional status outcomes for disorders of excessive sleepiness. Sleep 20: 835–843. [PubMed] [Google Scholar]

[pone.0103490-Acock1] 56.Acock AC (2013) Discovering Structural Equation Modeling using Stata. College Station, Texas: StataCorp LP. [Google Scholar]

[pone.0103490-CDC2] 57.(CDC) CfDCaP (2009) National Health and Nutrition Examination Surveys (NHANES 2005–06): Laboratory Procedure Manual: Fat Soluble Micronutrients (Vitamins A, E and Carotenoids) –UV-visible Detection.

[pone.0103490-CDC3] 58.(CDC) CfDCaP (2009) National Health and Nutrition Examination Surveys (NHANES 2005–06): Laboratory Procedure Manual: Vitamin C.

[pone.0103490-CDC4] 59.(CDC) CfDCaP (2008) Centers for Disease Control and Prevention (CDC). National Health and Nutrition Examination Surveys (NHANES 2005–06): Description of Laboratory Methodology: Vitamin B-12.

[pone.0103490-CDC5] 60.(CDC) CfDCaP (2008) National Health and Nutrition Examination Surveys (NHANES 2005–06): Description of Laboratory Methodology: Folate.

[pone.0103490-Abbott1] 61.Abbott Homocysteine (HCY) assay package insert fo IMX Analyzer.

[pone.0103490-Pernet1] 62. Pernet P, Lasnier E, Vaubourdolle M (2000) Evaluation of the AxSYM homocysteine assay and comparison with the IMx homocysteine assay. Clin Chem 46: 1440–1441. [PubMed] [Google Scholar]

[pone.0103490-CDC6] 63.(CDC) CfDCaP (2008) National Health and Nutrition Examination Surveys (NHANES 2005–06): Description of Laboratory Methodology: Vitamin D.

[pone.0103490-Cheng1] 64. Cheng YJ, Gregg EW, De Rekeneire N, Williams DE, Imperatore G, et al. (2007) Muscle-strengthening activity and its association with insulin sensitivity. Diabetes Care 30: 2264–2270. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Lagerros1] 65. Lagerros YT, Lagiou P (2007) Assessment of physical activity and energy expenditure in epidemiological research of chronic diseases. Eur J Epidemiol 22: 353–362. [DOI] [PubMed] [Google Scholar]

[pone.0103490-McCullough1] 66. McCullough ML, Feskanich D, Rimm EB, Giovannucci EL, Ascherio A, et al. (2000) Adherence to the Dietary Guidelines for Americans and risk of major chronic disease in men. Am J Clin Nutr 72: 1223–1231. [DOI] [PubMed] [Google Scholar]

[pone.0103490-United1] 67.United States Department of Agriculture (USDA) ARS Agriculture Research Service FSRG. Food and Nutrient Database for Dietary Studies, 3.0.

[pone.0103490-United2] 68.United States Department of Agriculture (USDA) ARS MyPyramid Equivalents Database for USDA Survey Food Codes Version 1.0

[pone.0103490-Center1] 69.Center for Disease Control and Prevention (CDC) (2010) National Health and Nutrition Examination Survey 1988–2008 Data Documentation, Codebook, and Frequencies

[pone.0103490-Foley1] 70. Foley D, Ancoli-Israel S, Britz P, Walsh J (2004) Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey. J Psychosom Res 56: 497–502. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Gottlieb1] 71. Gottlieb DJ, Punjabi NM, Newman AB, Resnick HE, Redline S, et al. (2005) Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med 165: 863–867. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Gottlieb2] 72. Gottlieb DJ, Redline S, Nieto FJ, Baldwin CM, Newman AB, et al. (2006) Association of usual sleep duration with hypertension: the Sleep Heart Health Study. Sleep 29: 1009–1014. [DOI] [PubMed] [Google Scholar]

[pone.0103490-STATA1] 73.STATA (2009) Statistics/Data Analysis: Release 11.0. College Station, TX: Stata Corporation. [Google Scholar]

[pone.0103490-Lohr1] 74.Lohr SL (2010) Sampling: Design and Analysis, 2nd Edition

[pone.0103490-Heckman1] 75. Heckman JJ (1979) Sample selection bias as a specification error. Econometrica 47: 153–161. [Google Scholar]

[pone.0103490-Puhani1] 76. Puhani P (2000) The Heckman Correction for sample selection and its critique. Journal of Economic Surveys 14: 53–68. [Google Scholar]

[pone.0103490-Hochberg1] 77.Hochberg Y, Tamhane, AC., (1987) Multiple comparison procedures. New York: Wiley. [Google Scholar]

[pone.0103490-Beydoun5] 78. Beydoun MA, Ding EL, Beydoun HA, Tanaka T, Ferrucci L, et al. (2012) Vitamin D receptor and megalin gene polymorphisms and their associations with longitudinal cognitive change in US adults. Am J Clin Nutr 95: 163–178. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Thakre1] 79. Thakre TP, Mamtani M, Ujaoney S, Kulkarni H (2012) Association of plasma homocysteine with self-reported sleep apnea is confounded by age: results from the national health and nutrition examination survey 2005–2006. Sleep Disord 2012: 634920. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Ryan1] 80. Ryan S, Nolan GM, Hannigan E, Cunningham S, Taylor C, et al. (2007) Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity. Thorax 62: 509–514. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0103490-Singh1] 81. Singh TD, Patial K, Vijayan VK, Ravi K (2009) Oxidative stress and obstructive sleep apnoea syndrome. Indian J Chest Dis Allied Sci 51: 217–224. [PubMed] [Google Scholar]

[pone.0103490-Golombek1] 82. Golombek DA, Rosenstein RE (2010) Physiology of circadian entrainment. Physiol Rev 90: 1063–1102. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Selhub1] 83. Selhub J (1999) Homocysteine metabolism. Annu Rev Nutr 19: 217–246. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Etchegaray1] 84. Etchegaray JP, Lee C, Wade PA, Reppert SM (2003) Rhythmic histone acetylation underlies transcription in the mammalian circadian clock. Nature 421: 177–182. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Ripperger1] 85. Ripperger JA, Merrow M (2011) Perfect timing: epigenetic regulation of the circadian clock. FEBS Lett 585: 1406–1411. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Ohta1] 86. Ohta T, Ando K, Iwata T, Ozaki N, Kayukawa Y, et al. (1991) Treatment of persistent sleep-wake schedule disorders in adolescents with methylcobalamin (vitamin B12). Sleep 14: 414–418. [PubMed] [Google Scholar]

[pone.0103490-Challet1] 87. Challet E, Dumont S, Mehdi MK, Allemann C, Bousser T, et al. (2013) Aging-like circadian disturbances in folate-deficient mice. Neurobiol Aging 34: 1589–1598. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Musiol1] 88. Musiol IM, Stumpf WE, Bidmon HJ, Heiss C, Mayerhofer A, et al. (1992) Vitamin D nuclear binding to neurons of the septal, substriatal and amygdaloid area in the Siberian hamster (Phodopus sungorus) brain. Neuroscience 48: 841–848. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Gominak1] 89. Gominak SC, Stumpf WE (2012) The world epidemic of sleep disorders is linked to vitamin D deficiency. Med Hypotheses 79: 132–135. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Mey1] 90. Mey J, McCaffery P (2004) Retinoic acid signaling in the nervous system of adult vertebrates. Neuroscientist 10: 409–421. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Maret1] 91. Maret S, Franken P, Dauvilliers Y, Ghyselinck NB, Chambon P, et al. (2005) Retinoic acid signaling affects cortical synchrony during sleep. Science 310: 111–113. [DOI] [PubMed] [Google Scholar]

[pone.0103490-Kitaoka1] 92. Kitaoka K, Shimizu M, Shimizu N, Chikahisa S, Nakagomi M, et al. (2011) Retinoic acid receptor antagonist LE540 attenuates wakefulness via the dopamine D1 receptor in mice. Brain Res 1423: 10–16. [DOI] [PubMed] [Google Scholar]

PERMALINK

Serum Nutritional Biomarkers and Their Associations with Sleep among US Adults in Recent National Surveys

May A Beydoun

Alyssa A Gamaldo

Jose A Canas

Hind A Beydoun

Mauli T Shah

Jessica M McNeely

Alan B Zonderman

Roles

Abstract

Background

Methods

Results

Conclusions

Introduction

Materials and Methods

Database and study subjects

Outcome assessment: Sleep quantity and quality measures

Nutritional Biomarker assays

Covariates

Statistical analysis

Results

Study sample characteristics

Table 1. Selected baseline characteristics of NHANES 2005–06 participants by sleep duration categories (n = 2,459)1 , 2.

Socio-demographic, lifestyle and dietary predictors of nutritional biomarkers

Table 2. Socio-demographic, lifestyle and dietary predictors of nutritional biomarkers (retinol, retinyl esters, vitamin C, vitamin E and total carotenoids): OLS multiple regression analyses; NHANES 2005–06 (n = 2,459).

Table 3. Socio-demographic, lifestyle and dietary predictors of nutritional biomarkers (folate, vitamin B-12, tHcy and 25(OH)D): OLS multiple regression analyses; NHANES 2005–06 (n = 2,459).

Nutritional biomarkers' association with sleep quantity and quality

Table 4. Associations between serum nutritional biomarkers (per 1 SD increase) and sleep quality measures: Multiple OLS and logistic regression models, controlling for dietary intakes or supplement use: 2-stage Heckman selection models (N = 2,346); NHANES 2005–061.

Sleep disorders and their association with serum nutritional biomarkers

Figure 1. Relative risk ratio (RRR with 95% CI) per 1 SD nutritional biomarker: (A) Insomnia vs. Normal sleep durationa,b, (B) Other sleep disorder categories vs. Nonea,b.

Sleep durations and their association with serum nutritional biomarkers

Figure 2. Relative risk ratio (RRR with 95% CI) per 1 SD nutritional biomarker: (A) Very short sleep vs. Normal sleep durationa,b, (B) Short sleep vs. Normal sleep durationa,b, (C) Long sleep vs. Normal sleep durationa,b.

Discussion

Nutritional biomarkers, diet and sleep: previous studies

Potential biological mechanisms of the association of B-vitamins, vitamin D and pro-vitamin A carotenoids with sleep

Strengths and limitations

Conclusion

Supporting Information

Acknowledgments

Funding Statement

References

Associated Data

Supplementary Materials

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases

Table 1. Selected baseline characteristics of NHANES 2005–06 participants by sleep duration categories (n = 2,459)¹ ^, ².

Table 4. Associations between serum nutritional biomarkers (per 1 SD increase) and sleep quality measures: Multiple OLS and logistic regression models, controlling for dietary intakes or supplement use: 2-stage Heckman selection models (N = 2,346); NHANES 2005–06¹.

Figure 1. Relative risk ratio (RRR with 95% CI) per 1 SD nutritional biomarker: (A) Insomnia vs. Normal sleep duration^a,b, (B) Other sleep disorder categories vs. None^a,b.

Figure 2. Relative risk ratio (RRR with 95% CI) per 1 SD nutritional biomarker: (A) Very short sleep vs. Normal sleep duration^a,b, (B) Short sleep vs. Normal sleep duration^a,b, (C) Long sleep vs. Normal sleep duration^a,b.